

CHANGE OF ACCOUNTING PERIOD

Form 990
Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations)

Do not enter social security numbers on this form as it may be made public.
Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No 1545-0047
2017
Open to Public Inspection

Form 990 header section including: A For the 2017 calendar year, or tax year beginning 01/01, 2017, and ending 09/30, 2017; B Check if applicable; C Name of organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION; D Employer identification number 33-1092191; E Telephone number (602) 343-8411; F Name and address of principal officer MICHAEL BASSOFF; G Gross receipts \$ 8,384,936; H(a) Is this a group return for subsidiaries? Yes X No; H(b) Are all subsidiaries included? Yes; I Tax-exempt status X 501(c)(3); J Website WWW.HELPTGEN.ORG; K Form of organization X Corporation; L Year of formation 2004; M State of legal domicile AZ

Part I Summary table with columns for Activities & Governance, Revenue, Expenses, and Net Assets or Fund Balances. Rows include mission statement, governance details, revenue breakdown, expenses, and net assets for Prior Year and Current Year.

Part II Signature Block
Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge

Signature Block section including: Sign Here (Signature of officer MANUEL ESTRADA, Date 8/13/18); Paid Preparer Use Only (Preparer's name JUSTIN CALTABIANO, Date 8/9/2018, Firm's name ERNST & YOUNG U.S. LLP, Firm's EIN 34-6565596)

May the IRS discuss this return with the preparer shown above? (see instructions) X Yes No
For Paperwork Reduction Act Notice, see the separate instructions. Form 990 (2017)

SCANNED OCT 17 2018

Part III Statement of Program Service Accomplishments

Check if Schedule O contains a response or note to any line in this Part III X

1 Briefly describe the organization's mission

BIOGENOMIC MEDICAL RESEARCH FUNDRAISING FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN).

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? Yes No

If "Yes," describe these new services on Schedule O

3 Did the organization cease conducting, or make significant changes in how it conducts, any program services? Yes No

If "Yes," describe these changes on Schedule O

4 Describe the organization's program service accomplishments for each of its three largest program services, as measured by expenses Section 501(c)(3) and 501(c)(4) organizations are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported

4a (Code _____) (Expenses \$ 3,532,132 including grants of \$ 3,532,132) (Revenue \$ 0)
SEE SCHEDULE O

4b (Code _____) (Expenses \$ _____ including grants of \$ _____) (Revenue \$ _____)

4c (Code _____) (Expenses \$ _____ including grants of \$ _____) (Revenue \$ _____)

4d Other program services (Describe in Schedule O)
(Expenses \$ _____ including grants of \$ _____) (Revenue \$ _____)

4e Total program service expenses **▶** 3,532,132.

BADMIOR

Part IV Checklist of Required Schedules

Table with 3 columns: Question number, Yes, No. Contains 19 numbered questions regarding organizational requirements and schedules.

Part IV Checklist of Required Schedules (continued)

	Yes	No
20a Did the organization operate one or more hospital facilities? <i>If "Yes," complete Schedule H.</i>		X
b If "Yes" to line 20a, did the organization attach a copy of its audited financial statements to this return?		
21 Did the organization report more than \$5,000 of grants or other assistance to any domestic organization or domestic government on Part IX, column (A), line 1? <i>If "Yes," complete Schedule I, Parts I and II.</i>	X	
22 Did the organization report more than \$5,000 of grants or other assistance to or for domestic individuals on Part IX, column (A), line 2? <i>If "Yes," complete Schedule I, Parts I and III.</i>		X
23 Did the organization answer "Yes" to Part VII, Section A, line 3, 4, or 5 about compensation of the organization's current and former officers, directors, trustees, key employees, and highest compensated employees? <i>If "Yes," complete Schedule J.</i>		X
24a Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than \$100,000 as of the last day of the year, that was issued after December 31, 2002? <i>If "Yes," answer lines 24b through 24d and complete Schedule K. If "No," go to line 25a.</i>		X
b Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?		
c Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?		
d Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?		
25a Section 501(c)(3), 501(c)(4), and 501(c)(29) organizations. Did the organization engage in an excess benefit transaction with a disqualified person during the year? <i>If "Yes," complete Schedule L, Part I.</i>		X
b Is the organization aware that it engaged in an excess benefit transaction with a disqualified person in a prior year, and that the transaction has not been reported on any of the organization's prior Forms 990 or 990-EZ? <i>If "Yes," complete Schedule L, Part I.</i>		X
26 Did the organization report any amount on Part X, line 5, 6, or 22 for receivables from or payables to any current or former officers, directors, trustees, key employees, highest compensated employees, or disqualified persons? <i>If "Yes," complete Schedule L, Part II.</i>		X
27 Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, substantial contributor or employee thereof, a grant selection committee member, or to a 35% controlled entity or family member of any of these persons? <i>If "Yes," complete Schedule L, Part III.</i>		X
28 Was the organization a party to a business transaction with one of the following parties (see Schedule L, Part IV instructions for applicable filing thresholds, conditions, and exceptions)		
a A current or former officer, director, trustee, or key employee? <i>If "Yes," complete Schedule L, Part IV.</i>		X
b A family member of a current or former officer, director, trustee, or key employee? <i>If "Yes," complete Schedule L, Part IV.</i>		X
c An entity of which a current or former officer, director, trustee, or key employee (or a family member thereof) was an officer, director, trustee, or direct or indirect owner? <i>If "Yes," complete Schedule L, Part IV.</i>		X
29 Did the organization receive more than \$25,000 in non-cash contributions? <i>If "Yes," complete Schedule M.</i>	X	
30 Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? <i>If "Yes," complete Schedule M.</i>		X
31 Did the organization liquidate, terminate, or dissolve and cease operations? <i>If "Yes," complete Schedule N, Part I.</i>		X
32 Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? <i>If "Yes," complete Schedule N, Part II.</i>		X
33 Did the organization own 100% of an entity disregarded as separate from the organization under Regulations sections 301.7701-2 and 301.7701-3? <i>If "Yes," complete Schedule R, Part I.</i>		X
34 Was the organization related to any tax-exempt or taxable entity? <i>If "Yes," complete Schedule R, Part II, III, or IV, and Part V, line 1.</i>	X	
35a Did the organization have a controlled entity within the meaning of section 512(b)(13)?		X
b If "Yes" to line 35a, did the organization receive any payment from or engage in any transaction with a controlled entity within the meaning of section 512(b)(13)? <i>If "Yes," complete Schedule R, Part V, line 2.</i>		
36 Section 501(c)(3) organizations. Did the organization make any transfers to an exempt non-charitable related organization? <i>If "Yes," complete Schedule R, Part V, line 2.</i>		X
37 Did the organization conduct more than 5% of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? <i>If "Yes," complete Schedule R, Part VI.</i>		X
38 Did the organization complete Schedule O and provide explanations in Schedule O for Part VI, lines 11b and 19? Note. All Form 990 filers are required to complete Schedule O	X	

Part V Statements Regarding Other IRS Filings and Tax Compliance

Check if Schedule O contains a response or note to any line in this Part V [X]

Table with columns for question numbers (1a-14b), Yes/No checkboxes, and numerical input fields. Contains questions about Form 1096, Form W-2G, backup withholding, Form W-3, unrelated business gross income, foreign accounts, prohibited tax shelter transactions, annual gross receipts, and sponsoring organizations.

Part VI Governance, Management, and Disclosure For each "Yes" response to lines 2 through 7b below, and for a "No" response to line 8a, 8b, or 10b below, describe the circumstances, processes, or changes in Schedule O See instructions. Check if Schedule O contains a response or note to any line in this Part VI

Section A. Governing Body and Management

Table with 3 columns: Question, Yes, No. Rows include: 1a (23), 1b (19), 2, 3, 4, 5, 6, 7a, 7b, 8a, 8b, 9.

Section B. Policies (This Section B requests information about policies not required by the Internal Revenue Code.)

Table with 3 columns: Question, Yes, No. Rows include: 10a, 10b, 11a, 11b, 12a, 12b, 12c, 13, 14, 15a, 15b, 16a, 16b.

Section C. Disclosure

- 17 List the states with which a copy of this Form 990 is required to be filed ARIZONA
18 Section 6104 requires an organization to make its Forms 1023 (or 1024 if applicable), 990, and 990-T (Section 501(c)(3)s only) available for public inspection. Indicate how you made these available. Check all that apply.
19 Describe in Schedule O whether (and if so, how) the organization made its governing documents, conflict of interest policy, and financial statements available to the public during the tax year
20 State the name, address, and telephone number of the person who possesses the organization's books and records

Part VII Compensation of Officers, Directors, Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors

Check if Schedule O contains a response or note to any line in this Part VII.

Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed Report compensation for the calendar year ending with or within the organization's tax year

- List all of the organization's **current** officers, directors, trustees (whether individuals or organizations), regardless of amount of compensation Enter -0- in columns (D), (E), and (F) if no compensation was paid
- List all of the organization's **current** key employees, if any See instructions for definition of "key employee "
- List the organization's five **current** highest compensated employees (other than an officer, director, trustee, or key employee) who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than \$100,000 from the organization and any related organizations
- List all of the organization's **former** officers, key employees, and highest compensated employees who received more than \$100,000 of reportable compensation from the organization and any related organizations
- List all of the organization's **former** directors or trustees that received, in the capacity as a former director or trustee of the organization, more than \$10,000 of reportable compensation from the organization and any related organizations

List persons in the following order individual trustees or directors, institutional trustees, officers, key employees, highest compensated employees, and former such persons

Check this box if neither the organization nor any related organization compensated any current officer, director, or trustee

(A) Name and Title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(1) MICHAEL BASSOFF PRESIDENT, TGEN FOUNDATION	24.00 16.00	X		X				0.	0.	0.
(2) BENNETT DORRANCE BOARD MEMBER/CHAIRMAN	1.00 1.00	X		X				0.	0.	0.
(3) RICHARD J. LEHMANN BOARD MEMBER/TREASURER	1.00 0.	X		X				0.	0.	0.
(4) KEN KENDRICK BOARD MEMBER/SECRETARY	1.00 0.	X		X				0.	0.	0.
(5) TERESA BURLESON BOARD MEMBER/ASST SEC/ASST TRE	1.00 39.00	X		X				0.	0.	0.
(6) KARL ELLER BOARD MEMBER	1.00 0.	X						0.	0.	0.
(7) PHIL FRANCIS BOARD MEMBER	1.00 0.	X						0.	0.	0.
(8) DIANE HALLE BOARD MEMBER (THRU 3/9/17)	1.00 0.	X						0.	0.	0.
(9) STEVE HILTON BOARD MEMBER	1.00 0.	X						0.	0.	0.
(10) CARRIE HULBURD BOARD MEMBER	1.00 0.	X						0.	0.	0.
(11) MIKE INGRAM BOARD MEMBER	1.00 0.	X						0.	0.	0.
(12) CATHERINE IVY BOARD MEMBER (THRU 4/25/17)	1.00 0.	X						0.	0.	0.
(13) MICHAEL KAPLAN BOARD MEMBER	1.00 0.	X						0.	0.	0.
(14) DAVID LANE BOARD MEMBER	1.00 0.	X						0.	0.	0.

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

(A) Name and title	(B) Average hours per week (list any hours for related organizations below dotted line)	(C) Position (do not check more than one box, unless person is both an officer and a director/trustee)						(D) Reportable compensation from the organization (W-2/1099-MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual trustee or director	Institutional trustee	Officer	Key employee	Highest compensated employee	Former			
(15) TERRY LEE ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(16) RANDY MAY ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(17) ARTE MORENO ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(18) F. FRANCIS NAJAFI ----- BOARD MEMBER (THRU 6/9/17)	1.00 0.	X						0.	0.	0.
(19) BILL POPE ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(20) WILLIAM J. POST ----- BOARD MEMBER	1.00 1.00	X						0.	0.	0.
(21) J. DANFORTH QUAYLE ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(22) TROY RICHARDS ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(23) STEVE STAGNER ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(24) RAY THURSTON ----- BOARD MEMBER	1.00 0.	X						0.	0.	0.
(25) JEFFREY M. TRENT, PH.D. ----- BOARD MEMBER	1.00 39.00	X						0.	0.	0.
1b Sub-total								0.	0.	0.
c Total from continuation sheets to Part VII, Section A								0.	0.	0.
d Total (add lines 1b and 1c)								0.	0.	0.

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization **0.**

	Yes	No
3 Did the organization list any former officer, director, or trustee, key employee, or highest compensated employee on line 1a? If "Yes," complete Schedule J for such individual		X
4 For any individual listed on line 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than \$150,000? If "Yes," complete Schedule J for such individual		X
5 Did any person listed on line 1a receive or accrue compensation from any unrelated organization or individual for services rendered to the organization? If "Yes," complete Schedule J for such person		X

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization Report compensation for the calendar year ending with or within the organization's tax year

(A) Name and business address	(B) Description of services	(C) Compensation

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 in compensation from the organization **0.**

Part VII Section A. Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees (continued)

Table with 6 main columns: (A) Name and title, (B) Average hours per week, (C) Position, (D) Reportable compensation from the organization, (E) Reportable compensation from related organizations, (F) Estimated amount of other compensation. Includes entries for HOWARD YOUNG and MANUEL ESTRADA.

1b Sub-total
c Total from continuation sheets to Part VII, Section A
d Total (add lines 1b and 1c)

2 Total number of individuals (including but not limited to those listed above) who received more than \$100,000 of reportable compensation from the organization

Table with 3 columns: Question number, Yes, No. Contains questions 3, 4, and 5 regarding compensation reporting.

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than \$100,000 of compensation from the organization Report compensation for the calendar year ending with or within the organization's tax year

Table with 3 columns: (A) Name and business address, (B) Description of services, (C) Compensation

2 Total number of independent contractors (including but not limited to those listed above) who received more than \$100,000 in compensation from the organization

Part VIII Statement of Revenue

Check if Schedule O contains a response or note to any line in this Part VIII.

			(A) Total revenue	(B) Related or exempt function revenue	(C) Unrelated business revenue	(D) Revenue excluded from tax under sections 512-514	
Contributions, Gifts, Grants and Other Similar Amounts	1a Federated campaigns	1a					
	b Membership dues	1b					
	c Fundraising events	1c					
	d Related organizations	1d					
	e Government grants (contributions)	1e					
	f All other contributions, gifts, grants, and similar amounts not included above	1f	8,383,173				
	g Noncash contributions included in lines 1a-1f \$		60,000				
	h Total. Add lines 1a-1f		8,383,173				
Program Service Revenue	2a _____	Business Code					
	b _____						
	c _____						
	d _____						
	e _____						
	f All other program service revenue						
	g Total. Add lines 2a-2f		0				
Other Revenue	3 Investment income (including dividends, interest, and other similar amounts).		1,763			1,763	
	4 Income from investment of tax-exempt bond proceeds		0				
	5 Royalties		0				
	6a Gross rents	(i) Real	(ii) Personal				
		b Less rental expenses					
		c Rental income or (loss)					
		d Net rental income or (loss).		0			
	7a Gross amount from sales of assets other than inventory	(i) Securities	(ii) Other				
		b Less cost or other basis and sales expenses					
		c Gain or (loss)					
		d Net gain or (loss)		0			
	8a Gross income from fundraising events (not including \$ _____ of contributions reported on line 1c) See Part IV, line 18	a					
		b Less direct expenses	b				
		c Net income or (loss) from fundraising events		0			
	9a Gross income from gaming activities See Part IV, line 19	a					
b Less direct expenses		b					
c Net income or (loss) from gaming activities			0				
10a Gross sales of inventory, less returns and allowances	a						
	b Less cost of goods sold	b					
	c Net income or (loss) from sales of inventory		0				
Miscellaneous Revenue		Business Code					
11a _____							
b _____							
c _____							
d All other revenue							
e Total. Add lines 11a-11d		0					
12 Total revenue. See instructions		8,384,936			1,763		

Part IX Statement of Functional Expenses

Section 501(c)(3) and 501(c)(4) organizations must complete all columns. All other organizations must complete column (A)

Check if Schedule O contains a response or note to any line in this Part IX

Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1 Grants and other assistance to domestic organizations and domestic governments See Part IV, line 21	3,532,132.	3,532,132.		
2 Grants and other assistance to domestic individuals See Part IV, line 22	0.			
3 Grants and other assistance to foreign organizations, foreign governments, and foreign individuals See Part IV, lines 15 and 16	0.			
4 Benefits paid to or for members	0.			
5 Compensation of current officers, directors, trustees, and key employees	352,329.		35,233.	317,096.
6 Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)	0.			
7 Other salaries and wages	332,304.		99,691.	232,613.
8 Pension plan accruals and contributions (include section 401(k) and 403(b) employer contributions)	0.			
9 Other employee benefits	0.			
10 Payroll taxes	0.			
11 Fees for services (non-employees)				
a Management	0.			
b Legal	1,110.		1,110.	
c Accounting	0.			
d Lobbying	0.			
e Professional fundraising services See Part IV, line 17.	0.			
f Investment management fees	0.			
g Other (If line 11g amount exceeds 10% of line 25, column (A) amount, list line 11g expenses on Schedule O).	26,108.		26,108.	
12 Advertising and promotion	58,607.		5,861.	52,746.
13 Office expenses	123,773.		12,377.	111,396.
14 Information technology	10,354.		1,035.	9,319.
15 Royalties	0.			
16 Occupancy	66,670.		6,667.	60,003.
17 Travel	74,585.		7,459.	67,126.
18 Payments of travel or entertainment expenses for any federal, state, or local public officials	0.			
19 Conferences, conventions, and meetings	144,732.		14,473.	130,259.
20 Interest	0.			
21 Payments to affiliates	0.			
22 Depreciation, depletion, and amortization	0.			
23 Insurance	0.			
24 Other expenses Itemize expenses not covered above (List miscellaneous expenses in line 24e. If line 24e amount exceeds 10% of line 25, column (A) amount, list line 24e expenses on Schedule O)				
a DUES AND SUBSCRIPTIONS	5,346.		5,346.	
b RECRUITMENT	245.		245.	
c ALL OTHER EXPENSES	887.		887.	
d				
e All other expenses				
25 Total functional expenses. Add lines 1 through 24e	4,729,182.	3,532,132.	216,492.	980,558.
26 Joint costs. Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation. Check here <input type="checkbox"/> if following SOP 98-2 (ASC 958-720)	0.			

Part X Balance Sheet

Check if Schedule O contains a response or note to any line in this Part X.

		(A) Beginning of year		(B) End of year
Assets	1 Cash - non-interest-bearing	23,026.	1	44,145.
	2 Savings and temporary cash investments	14,736,921.	2	13,797,322.
	3 Pledges and grants receivable, net	8,717,952.	3	11,653,447.
	4 Accounts receivable, net	1,838.	4	1,225.
	5 Loans and other receivables from current and former officers, directors, trustees, key employees, and highest compensated employees Complete Part II of Schedule L	0.	5	0.
	6 Loans and other receivables from other disqualified persons (as defined under section 4958(f)(1)), persons described in section 4958(c)(3)(B), and contributing employers and sponsoring organizations of section 501(c)(9) voluntary employees' beneficiary organizations (see instructions) Complete Part II of Schedule L	0.	6	0.
	7 Notes and loans receivable, net	0.	7	0.
	8 Inventories for sale or use	3,621.	8	0.
	9 Prepaid expenses and deferred charges	7,408.	9	23,540.
	10a Land, buildings, and equipment cost or other basis Complete Part VI of Schedule D 10a			
	b Less accumulated depreciation 10b	0.	10c	0.
	11 Investments - publicly traded securities	0.	11	0.
	12 Investments - other securities See Part IV, line 11	0.	12	0.
	13 Investments - program-related See Part IV, line 11	0.	13	0.
	14 Intangible assets	0.	14	0.
	15 Other assets See Part IV, line 11	0.	15	60,000.
16 Total assets. Add lines 1 through 15 (must equal line 34)	23,490,766.	16	25,579,679.	
Liabilities	17 Accounts payable and accrued expenses	8,913,356.	17	7,347,254.
	18 Grants payable	0.	18	0.
	19 Deferred revenue	1,234.	19	7.
	20 Tax-exempt bond liabilities	0.	20	0.
	21 Escrow or custodial account liability Complete Part IV of Schedule D	0.	21	0.
	22 Loans and other payables to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified persons Complete Part II of Schedule L	0.	22	0.
	23 Secured mortgages and notes payable to unrelated third parties	0.	23	0.
	24 Unsecured notes and loans payable to unrelated third parties	0.	24	0.
	25 Other liabilities (including federal income tax, payables to related third parties, and other liabilities not included on lines 17-24) Complete Part X of Schedule D	0.	25	0.
	26 Total liabilities. Add lines 17 through 25.	8,914,590.	26	7,347,261.
Net Assets or Fund Balances	Organizations that follow SFAS 117 (ASC 958), check here <input checked="" type="checkbox"/> and complete lines 27 through 29, and lines 33 and 34.			
	27 Unrestricted net assets	-5,436,204.	27	-6,267,703.
	28 Temporarily restricted net assets	19,950,287.	28	24,438,028.
	29 Permanently restricted net assets	62,093.	29	62,093.
	Organizations that do not follow SFAS 117 (ASC 958), check here <input type="checkbox"/> and complete lines 30 through 34.			
	30 Capital stock or trust principal, or current funds		30	
	31 Paid-in or capital surplus, or land, building, or equipment fund		31	
	32 Retained earnings, endowment, accumulated income, or other funds		32	
33 Total net assets or fund balances	14,576,176.	33	18,232,418.	
34 Total liabilities and net assets/fund balances	23,490,766.	34	25,579,679.	

Part XI Reconciliation of Net Assets

Check if Schedule O contains a response or note to any line in this Part XI.

1	Total revenue (must equal Part VIII, column (A), line 12)	1	8,384,936.
2	Total expenses (must equal Part IX, column (A), line 25)	2	4,729,182.
3	Revenue less expenses Subtract line 2 from line 1	3	3,655,754.
4	Net assets or fund balances at beginning of year (must equal Part X, line 33, column (A))	4	14,576,176.
5	Net unrealized gains (losses) on investments	5	488.
6	Donated services and use of facilities	6	0.
7	Investment expenses	7	0.
8	Prior period adjustments	8	0.
9	Other changes in net assets or fund balances (explain in Schedule O)	9	0.
10	Net assets or fund balances at end of year Combine lines 3 through 9 (must equal Part X, line 33, column (B))	10	18,232,418.

Part XII Financial Statements and Reporting

Check if Schedule O contains a response or note to any line in this Part XII.

	Yes	No
1 Accounting method used to prepare the Form 990 <input type="checkbox"/> Cash <input checked="" type="checkbox"/> Accrual <input type="checkbox"/> Other _____ If the organization changed its method of accounting from a prior year or checked "Other," explain in Schedule O		
2a Were the organization's financial statements compiled or reviewed by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were compiled or reviewed on a separate basis, consolidated basis, or both <input type="checkbox"/> Separate basis <input type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis		X
b Were the organization's financial statements audited by an independent accountant? If "Yes," check a box below to indicate whether the financial statements for the year were audited on a separate basis, consolidated basis, or both <input type="checkbox"/> Separate basis <input checked="" type="checkbox"/> Consolidated basis <input type="checkbox"/> Both consolidated and separate basis	X	
c If "Yes" to line 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant? If the organization changed either its oversight process or selection process during the tax year, explain in Schedule O	X	
3a As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?		X
b If "Yes," did the organization undergo the required audit or audits? If the organization did not undergo the required audit or audits, explain why in Schedule O and describe any steps taken to undergo such audits		

SCHEDULE A
(Form 990 or 990-EZ)

Public Charity Status and Public Support

OMB No 1545-0047

2017

Open to Public Inspection

Department of the Treasury
Internal Revenue Service

Complete if the organization is a section 501(c)(3) organization or a section 4947(a)(1) nonexempt charitable trust.

▶ Attach to Form 990 or Form 990-EZ.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

Name of the organization **THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION**

Employer identification number
33-1092191

Part I Reason for Public Charity Status (All organizations must complete this part) See instructions

The organization is not a private foundation because it is (For lines 1 through 12, check only one box)

- 1 A church, convention of churches, or association of churches described in **section 170(b)(1)(A)(i)**.
- 2 A school described in **section 170(b)(1)(A)(ii)**. (Attach Schedule E (Form 990 or 990-EZ))
- 3 A hospital or a cooperative hospital service organization described in **section 170(b)(1)(A)(iii)**.
- 4 A medical research organization operated in conjunction with a hospital described in **section 170(b)(1)(A)(iii)**. Enter the hospital's name, city, and state _____
- 5 An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **section 170(b)(1)(A)(iv)**. (Complete Part II)
- 6 A federal, state, or local government or governmental unit described in **section 170(b)(1)(A)(v)**.
- 7 An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **section 170(b)(1)(A)(vi)**. (Complete Part II)
- 8 A community trust described in **section 170(b)(1)(A)(vi)**. (Complete Part II)
- 9 An agricultural research organization described in **section 170(b)(1)(A)(ix)** operated in conjunction with a land-grant college or university or a non-land-grant college of agriculture (see instructions) Enter the name, city, and state of the college or university _____
- 10 An organization that normally receives (1) more than 33 1/3 % of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions - subject to certain exceptions, and (2) no more than 33 1/3 % of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975 See **section 509(a)(2)**. (Complete Part III)
- 11 An organization organized and operated exclusively to test for public safety See **section 509(a)(4)**.
- 12 An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in **section 509(a)(1)** or **section 509(a)(2)**. See **section 509(a)(3)**. Check the box in lines 12a through 12d that describes the type of supporting organization and complete lines 12e, 12f, and 12g
 - a **Type I** A supporting organization operated, supervised, or controlled by its supported organization(s), typically by giving the supported organization(s) the power to regularly appoint or elect a majority of the directors or trustees of the supporting organization **You must complete Part IV, Sections A and B.**
 - b **Type II** A supporting organization supervised or controlled in connection with its supported organization(s), by having control or management of the supporting organization vested in the same persons that control or manage the supported organization(s) **You must complete Part IV, Sections A and C.**
 - c **Type III functionally integrated.** A supporting organization operated in connection with, and functionally integrated with, its supported organization(s) (see instructions) **You must complete Part IV, Sections A, D, and E.**
 - d **Type III non-functionally integrated.** A supporting organization operated in connection with its supported organization(s) that is not functionally integrated The organization generally must satisfy a distribution requirement and an attentiveness requirement (see instructions) **You must complete Part IV, Sections A and D, and Part V.**
 - e Check this box if the organization received a written determination from the IRS that it is a Type I, Type II, Type III functionally integrated, or Type III non-functionally integrated supporting organization
 - f Enter the number of supported organizations.
 - g Provide the following information about the supported organization(s)

(i) Name of supported organization	(ii) EIN	(iii) Type of organization (described on lines 1-10 above (see instructions))	(iv) Is the organization listed in your governing document?		(v) Amount of monetary support (see instructions)	(vi) Amount of other support (see instructions)
			Yes	No		
(A)						
(B)						
(C)						
(D)						
(E)						
Total						

Part II Support Schedule for Organizations Described in Sections 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)
 (Complete only if you checked the box on line 5, 7, or 8 of Part I or if the organization failed to qualify under Part III. If the organization fails to qualify under the tests listed below, please complete Part III.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
1 Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants")	12,174,321	13,561,515	9,117,401	5,831,237	8,383,173	49,067,647
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						0
3 The value of services or facilities furnished by a governmental unit to the organization without charge						0
4 Total. Add lines 1 through 3	12,174,321	13,561,515	9,117,401	5,831,237	8,383,173	49,067,647
5 The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).						13,287,617
6 Public support. Subtract line 5 from line 4						35,780,030

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
7 Amounts from line 4	12,174,321	13,561,515	9,117,401	5,831,237	8,383,173	49,067,647
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources	947	1,004	1,005		1,763	4,719
9 Net income from unrelated business activities, whether or not the business is regularly carried on						0
10 Other income. Do not include gain or loss from the sale of capital assets (Explain in Part VI)						0
11 Total support. Add lines 7 through 10						49,072,366
12 Gross receipts from related activities, etc. (see instructions)					12	
13 First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here						<input type="checkbox"/>

Section C. Computation of Public Support Percentage

14 Public support percentage for 2017 (line 6, column (f) divided by line 11, column (f)).	14	72.91%
15 Public support percentage from 2016 Schedule A, Part II, line 14	15	76.37%
16a 33 1/3% support test - 2017. If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization.		<input checked="" type="checkbox"/>
b 33 1/3% support test - 2016. If the organization did not check a box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and stop here. The organization qualifies as a publicly supported organization		<input type="checkbox"/>
17a 10%-facts-and-circumstances test - 2017. If the organization did not check a box on line 13, 16a, or 16b, and line 14 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization.		<input type="checkbox"/>
b 10%-facts-and-circumstances test - 2016. If the organization did not check a box on line 13, 16a, 16b, or 17a, and line 15 is 10% or more, and if the organization meets the "facts-and-circumstances" test, check this box and stop here. Explain in Part VI how the organization meets the "facts-and-circumstances" test. The organization qualifies as a publicly supported organization		<input type="checkbox"/>
18 Private foundation. If the organization did not check a box on line 13, 16a, 16b, 17a, or 17b, check this box and see instructions		<input type="checkbox"/>

Part III Support Schedule for Organizations Described in Section 509(a)(2)

(Complete only if you checked the box on line 10 of Part I or if the organization failed to qualify under Part II. If the organization fails to qualify under the tests listed below, please complete Part II.)

Section A. Public Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
1 Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants.")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 Total. Add lines 1 through 5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of \$5,000 or 1% of the amount on line 13 for the year						
c Add lines 7a and 7b.						
8 Public support. (Subtract line 7c from line 6)						

Section B. Total Support

Calendar year (or fiscal year beginning in) ▶	(a) 2013	(b) 2014	(c) 2015	(d) 2016	(e) 2017	(f) Total
9 Amounts from line 6.						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties, and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on						
12 Other income Do not include gain or loss from the sale of capital assets (Explain in Part VI)						
13 Total support. (Add lines 9, 10c, 11, and 12)						

14 First five years. If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a section 501(c)(3) organization, check this box and stop here.

Section C. Computation of Public Support Percentage

15 Public support percentage for 2017 (line 8, column (f) divided by line 13, column (f)).	15	%
16 Public support percentage from 2016 Schedule A, Part III, line 15	16	%

Section D. Computation of Investment Income Percentage

17 Investment income percentage for 2017 (line 10c, column (f) divided by line 13, column (f))	17	%
18 Investment income percentage from 2016 Schedule A, Part III, line 17	18	%

19a 33 1/3% support tests - 2017. If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization.

b 33 1/3% support tests - 2016. If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3%, and line 18 is not more than 33 1/3%, check this box and stop here. The organization qualifies as a publicly supported organization.

20 Private foundation If the organization did not check a box on line 14, 19a, or 19b, check this box and see instructions

Part IV Supporting Organizations

(Complete only if you checked a box in line 12 on Part I. If you checked 12a of Part I, complete Sections A and B. If you checked 12b of Part I, complete Sections A and C. If you checked 12c of Part I, complete Sections A, D, and E. If you checked 12d of Part I, complete Sections A and D, and complete Part V)

Section A. All Supporting Organizations

	Yes	No
1 Are all of the organization's supported organizations listed by name in the organization's governing documents? If "No," describe in Part VI how the supported organizations are designated. If designated by class or purpose, describe the designation. If historic and continuing relationship, explain.		
2 Did the organization have any supported organization that does not have an IRS determination of status under section 509(a)(1) or (2)? If "Yes," explain in Part VI how the organization determined that the supported organization was described in section 509(a)(1) or (2).		
3a Did the organization have a supported organization described in section 501(c)(4), (5), or (6)? If "Yes," answer (b) and (c) below.		
b Did the organization confirm that each supported organization qualified under section 501(c)(4), (5), or (6) and satisfied the public support tests under section 509(a)(2)? If "Yes," describe in Part VI when and how the organization made the determination.		
c Did the organization ensure that all support to such organizations was used exclusively for section 170(c)(2)(B) purposes? If "Yes," explain in Part VI what controls the organization put in place to ensure such use.		
4a Was any supported organization not organized in the United States ("foreign supported organization")? If "Yes," and if you checked 12a or 12b in Part I, answer (b) and (c) below.		
b Did the organization have ultimate control and discretion in deciding whether to make grants to the foreign supported organization? If "Yes," describe in Part VI how the organization had such control and discretion despite being controlled or supervised by or in connection with its supported organizations.		
c Did the organization support any foreign supported organization that does not have an IRS determination under sections 501(c)(3) and 509(a)(1) or (2)? If "Yes," explain in Part VI what controls the organization used to ensure that all support to the foreign supported organization was used exclusively for section 170(c)(2)(B) purposes.		
5a Did the organization add, substitute, or remove any supported organizations during the tax year? If "Yes," answer (b) and (c) below (if applicable). Also, provide detail in Part VI , including (i) the names and EIN numbers of the supported organizations added, substituted, or removed; (ii) the reasons for each such action, (iii) the authority under the organization's organizing document authorizing such action, and (iv) how the action was accomplished (such as by amendment to the organizing document).		
b Type I or Type II only. Was any added or substituted supported organization part of a class already designated in the organization's organizing document?		
c Substitutions only. Was the substitution the result of an event beyond the organization's control?		
6 Did the organization provide support (whether in the form of grants or the provision of services or facilities) to anyone other than (i) its supported organizations, (ii) individuals that are part of the charitable class benefited by one or more of its supported organizations, or (iii) other supporting organizations that also support or benefit one or more of the filing organization's supported organizations? If "Yes," provide detail in Part VI .		
7 Did the organization provide a grant, loan, compensation, or other similar payment to a substantial contributor (defined in section 4958(c)(3)(C)), a family member of a substantial contributor, or a 35% controlled entity with regard to a substantial contributor? If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ).		
8 Did the organization make a loan to a disqualified person (as defined in section 4958) not described in line 7? If "Yes," complete Part I of Schedule L (Form 990 or 990-EZ).		
9a Was the organization controlled directly or indirectly at any time during the tax year by one or more disqualified persons as defined in section 4946 (other than foundation managers and organizations described in section 509(a)(1) or (2))? If "Yes," provide detail in Part VI .		
b Did one or more disqualified persons (as defined in line 9a) hold a controlling interest in any entity in which the supporting organization had an interest? If "Yes," provide detail in Part VI .		
c Did a disqualified person (as defined in line 9a) have an ownership interest in, or derive any personal benefit from, assets in which the supporting organization also had an interest? If "Yes," provide detail in Part VI .		
10a Was the organization subject to the excess business holdings rules of section 4943 because of section 4943(f) (regarding certain Type II supporting organizations, and all Type III non-functionally integrated supporting organizations)? If "Yes," answer 10b below.		
b Did the organization have any excess business holdings in the tax year? (Use Schedule C, Form 4720, to determine whether the organization had excess business holdings.)		

Part IV Supporting Organizations (continued)

	Yes	No
11 Has the organization accepted a gift or contribution from any of the following persons?		
a A person who directly or indirectly controls, either alone or together with persons described in (b) and (c) below, the governing body of a supported organization?	11a	
b A family member of a person described in (a) above?	11b	
c A 35% controlled entity of a person described in (a) or (b) above? If "Yes" to a, b, or c, provide detail in Part VI .	11c	

Section B. Type I Supporting Organizations

	Yes	No
1 Did the directors, trustees, or membership of one or more supported organizations have the power to regularly appoint or elect at least a majority of the organization's directors or trustees at all times during the tax year? If "No," describe in Part VI how the supported organization(s) effectively operated, supervised, or controlled the organization's activities. If the organization had more than one supported organization, describe how the powers to appoint and/or remove directors or trustees were allocated among the supported organizations and what conditions or restrictions, if any, applied to such powers during the tax year.	1	
2 Did the organization operate for the benefit of any supported organization other than the supported organization(s) that operated, supervised, or controlled the supporting organization? If "Yes," explain in Part VI how providing such benefit carried out the purposes of the supported organization(s) that operated, supervised, or controlled the supporting organization.	2	

Section C. Type II Supporting Organizations

	Yes	No
1 Were a majority of the organization's directors or trustees during the tax year also a majority of the directors or trustees of each of the organization's supported organization(s)? If "No," describe in Part VI how control or management of the supporting organization was vested in the same persons that controlled or managed the supported organization(s).	1	

Section D. All Type III Supporting Organizations

	Yes	No
1 Did the organization provide to each of its supported organizations, by the last day of the fifth month of the organization's tax year, (i) a written notice describing the type and amount of support provided during the prior tax year, (ii) a copy of the Form 990 that was most recently filed as of the date of notification, and (iii) copies of the organization's governing documents in effect on the date of notification, to the extent not previously provided?	1	
2 Were any of the organization's officers, directors, or trustees either (i) appointed or elected by the supported organization(s) or (ii) serving on the governing body of a supported organization? If "No," explain in Part VI how the organization maintained a close and continuous working relationship with the supported organization(s).	2	
3 By reason of the relationship described in (2), did the organization's supported organizations have a significant voice in the organization's investment policies and in directing the use of the organization's income or assets at all times during the tax year? If "Yes," describe in Part VI the role the organization's supported organizations played in this regard.	3	

Section E. Type III Functionally Integrated Supporting Organizations

1 Check the box next to the method that the organization used to satisfy the Integral Part Test during the year (see instructions).			
a <input type="checkbox"/> The organization satisfied the Activities Test. Complete line 2 below.			
b <input type="checkbox"/> The organization is the parent of each of its supported organizations. Complete line 3 below.			
c <input type="checkbox"/> The organization supported a governmental entity. Describe in Part VI how you supported a government entity (see instructions).			
2 Activities Test. Answer (a) and (b) below.		Yes	No
a Did substantially all of the organization's activities during the tax year directly further the exempt purposes of the supported organization(s) to which the organization was responsive? If "Yes," then in Part VI identify those supported organizations and explain how these activities directly furthered their exempt purposes, how the organization was responsive to those supported organizations, and how the organization determined that these activities constituted substantially all of its activities.	2a		
b Did the activities described in (a) constitute activities that, but for the organization's involvement, one or more of the organization's supported organization(s) would have been engaged in? If "Yes," explain in Part VI the reasons for the organization's position that its supported organization(s) would have engaged in these activities but for the organization's involvement.	2b		
3 Parent of Supported Organizations. Answer (a) and (b) below.			
a Did the organization have the power to regularly appoint or elect a majority of the officers, directors, or trustees of each of the supported organizations? Provide details in Part VI .	3a		
b Did the organization exercise a substantial degree of direction over the policies, programs, and activities of each of its supported organizations? If "Yes," describe in Part VI the role played by the organization in this regard.	3b		

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations

1 Check here if the organization satisfied the Integral Part Test as a qualifying trust on Nov. 20, 1970 (explain in Part VI). See instructions. All other Type III non-functionally integrated supporting organizations must complete Sections A through E.

Section A - Adjusted Net Income		(A) Prior Year	(B) Current Year (optional)
1	Net short-term capital gain	1	
2	Recoveries of prior-year distributions	2	
3	Other gross income (see instructions)	3	
4	Add lines 1 through 3	4	
5	Depreciation and depletion	5	
6	Portion of operating expenses paid or incurred for production or collection of gross income or for management, conservation, or maintenance of property held for production of income (see instructions)	6	
7	Other expenses (see instructions)	7	
8	Adjusted Net Income (subtract lines 5, 6, and 7 from line 4)	8	
Section B - Minimum Asset Amount		(A) Prior Year	(B) Current Year (optional)
1	Aggregate fair market value of all non-exempt-use assets (see instructions for short tax year or assets held for part of year)		
a	Average monthly value of securities	1a	
b	Average monthly cash balances	1b	
c	Fair market value of other non-exempt-use assets	1c	
d	Total (add lines 1a, 1b, and 1c)	1d	
e	Discount claimed for blockage or other factors (explain in detail in Part VI)		
2	Acquisition indebtedness applicable to non-exempt-use assets	2	
3	Subtract line 2 from line 1d	3	
4	Cash deemed held for exempt use. Enter 1-1/2% of line 3 (for greater amount, see instructions)	4	
5	Net value of non-exempt-use assets (subtract line 4 from line 3)	5	
6	Multiply line 5 by 0.35	6	
7	Recoveries of prior-year distributions	7	
8	Minimum Asset Amount (add line 7 to line 6)	8	
Section C - Distributable Amount			Current Year
1	Adjusted net income for prior year (from Section A, line 8, Column A)	1	
2	Enter 85% of line 1	2	
3	Minimum asset amount for prior year (from Section B, line 8, Column A)	3	
4	Enter greater of line 2 or line 3	4	
5	Income tax imposed in prior year	5	
6	Distributable Amount. Subtract line 5 from line 4, unless subject to emergency temporary reduction (see instructions)	6	
7	<input type="checkbox"/> Check here if the current year is the organization's first as a non-functionally integrated Type III supporting organization (see instructions)		

Schedule A (Form 990 or 990-EZ) 2017

Part V Type III Non-Functionally Integrated 509(a)(3) Supporting Organizations (continued)

Section D - Distributions		Current Year		
1	Amounts paid to supported organizations to accomplish exempt purposes			
2	Amounts paid to perform activity that directly furthers exempt purposes of supported organizations, in excess of income from activity			
3	Administrative expenses paid to accomplish exempt purposes of supported organizations			
4	Amounts paid to acquire exempt-use assets			
5	Qualified set-aside amounts (prior IRS approval required)			
6	Other distributions (describe in Part VI) See instructions			
7	Total annual distributions. Add lines 1 through 6			
8	Distributions to attentive supported organizations to which the organization is responsive (provide details in Part VI) See instructions			
9	Distributable amount for 2017 from Section C, line 6			
10	Line 8 amount divided by Line 9 amount			
Section E - Distribution Allocations (see instructions)		(i) Excess Distributions	(ii) Underdistributions Pre-2017	(iii) Distributable Amount for 2017
1	Distributable amount for 2017 from Section C, line 6			
2	Underdistributions, if any, for years prior to 2017 (reasonable cause required-explain in Part VI) See instructions			
3	Excess distributions carryover, if any, to 2017			
a				
b	From 2013			
c	From 2014			
d	From 2015			
e	From 2016			
f	Total of lines 3a through e			
g	Applied to underdistributions of prior years			
h	Applied to 2017 distributable amount			
i	Carryover from 2012 not applied (see instructions)			
j	Remainder Subtract lines 3g, 3h, and 3i from 3f			
4	Distributions for 2017 from Section D, line 7 \$			
a	Applied to underdistributions of prior years			
b	Applied to 2017 distributable amount			
c	Remainder Subtract lines 4a and 4b from 4			
5	Remaining underdistributions for years prior to 2017, if any Subtract lines 3g and 4a from line 2 For result greater than zero, explain in Part VI See instructions			
6	Remaining underdistributions for 2017 Subtract lines 3h and 4b from line 1 For result greater than zero, explain in Part VI See instructions			
7	Excess distributions carryover to 2018 Add lines 3j and 4c			
8	Breakdown of line 7			
a	Excess from 2013			
b	Excess from 2014			
c	Excess from 2015			
d	Excess from 2016			
e	Excess from 2017			

Part VI **Supplemental Information.** Provide the explanations required by Part II, line 10, Part II, line 17a or 17b; Part III, line 12, Part IV, Section A, lines 1, 2, 3b, 3c, 4b, 4c, 5a, 6, 9a, 9b, 9c, 11a, 11b, and 11c; Part IV, Section B, lines 1 and 2, Part IV, Section C, line 1, Part IV, Section D, lines 2 and 3; Part IV, Section E, lines 1c, 2a, 2b, 3a and 3b; Part V, line 1, Part V, Section B, line 1e, Part V, Section D, lines 5, 6, and 8; and Part V, Section E, lines 2, 5, and 6 Also complete this part for any additional information (See instructions.)

SCHEDULE A, PART II, COLUMN (E)

THE AMOUNTS INCLUDED IN PART II, COLUMN (E) ARE FOR A SHORT PERIOD,

01/01/2017 - 09/30/2017.

SCHEDULE D (Form 990)

Supplemental Financial Statements

OMB No 1545-0047

2017

Open to Public Inspection

Department of the Treasury Internal Revenue Service

Complete if the organization answered "Yes" on Form 990, Part IV, line 6, 7, 8, 9, 10, 11a, 11b, 11c, 11d, 11e, 11f, 12a, or 12b.

Attach to Form 990.

Go to www.irs.gov/Form990 for instructions and the latest information.

Name of the organization FOUNDATION THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number 33-1092191

Part I Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts. Complete if the organization answered "Yes" on Form 990, Part IV, line 6

Table with 2 columns: (a) Donor advised funds, (b) Funds and other accounts. Rows include: 1 Total number at end of year, 2 Aggregate value of contributions to (during year), 3 Aggregate value of grants from (during year), 4 Aggregate value at end of year, 5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control?, 6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds can be used only for charitable purposes and not for the benefit of the donor or donor advisor, or for any other purpose conferring impermissible private benefit?

Part II Conservation Easements. Complete if the organization answered "Yes" on Form 990, Part IV, line 7

Table with 2 columns: Held at the End of the Tax Year. Rows include: 1 Purpose(s) of conservation easements held by the organization (check all that apply), 2 Complete lines 2a through 2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year, 3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the tax year, 4 Number of states where property subject to conservation easement is located, 5 Does the organization have a written policy regarding the periodic monitoring, inspection, handling of violations, and enforcement of the conservation easements it holds?, 6 Staff and volunteer hours devoted to monitoring, inspecting, handling of violations, and enforcing conservation easements during the year, 7 Amount of expenses incurred in monitoring, inspecting, handling of violations, and enforcing conservation easements during the year, 8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and section 170(h)(4)(B)(ii)?, 9 In Part XIII, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets. Complete if the organization answered "Yes" on Form 990, Part IV, line 8

Table with 2 columns: Revenue, Assets. Rows include: 1a If the organization elected, as permitted under SFAS 116 (ASC 958), not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide, in Part XIII, the text of the footnote to its financial statements that describes these items, 1b If the organization elected, as permitted under SFAS 116 (ASC 958), to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items, 2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 (ASC 958) relating to these items

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule D (Form 990) 2017

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets (continued)

- 3 Using the organization's acquisition, accession, and other records, check any of the following that are a significant use of its collection items (check all that apply)
- a Public exhibition
 - b Scholarly research
 - c Preservation for future generations
 - d Loan or exchange programs
 - e Other _____
- 4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIII
- 5 During the year, did the organization solicit or receive donations of art, historical treasures, or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? Yes No

Part IV Escrow and Custodial Arrangements.

Complete if the organization answered "Yes" on Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21

- 1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? Yes No
- b If "Yes," explain the arrangement in Part XIII and complete the following table
- | | Amount |
|---------------------------------|--------|
| c Beginning balance | 1c |
| d Additions during the year | 1d |
| e Distributions during the year | 1e |
| f Ending balance | 1f |
- 2a Did the organization include an amount on Form 990, Part X, line 21, for escrow or custodial account liability? Yes No
- b If "Yes," explain the arrangement in Part XIII. Check here if the explanation has been provided on Part XIII

Part V Endowment Funds.

Complete if the organization answered "Yes" on Form 990, Part IV, line 10.

	(a) Current year	(b) Prior year	(c) Two years back	(d) Three years back	(e) Four years back
1a Beginning of year balance	62,093.	62,093.	62,093.	62,093.	62,093.
b Contributions	46,076.				
c Net investment earnings, gains, and losses	10,642.	8,904.	7,353.	6,500.	7,353.
d Grants or scholarships	4,658.				
e Other expenditures for facilities and programs	5,458.	8,904.	7,353.	6,500.	7,353.
f Administrative expenses					
g End of year balance	108,695.	62,093.	62,093.	62,093.	62,093.

- 2 Provide the estimated percentage of the current year end balance (line 1g, column (a)) held as
- a Board designated or quasi-endowment _____ %
 - b Permanent endowment 57.1300 %
 - c Temporarily restricted endowment 42.8700 %
- The percentages on lines 2a, 2b, and 2c should equal 100%
- 3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by
- | | Yes | No |
|-----------------------------|--------------------------|-------------------------------------|
| (i) unrelated organizations | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
| (ii) related organizations | <input type="checkbox"/> | <input checked="" type="checkbox"/> |
- b If "Yes" on line 3a(ii), are the related organizations listed as required on Schedule R?
- 4 Describe in Part XIII the intended uses of the organization's endowment funds

Part VI Land, Buildings, and Equipment.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11a. See Form 990, Part X, line 10

Description of property	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Accumulated depreciation	(d) Book value
1a Land				
b Buildings				
c Leasehold improvements				
d Equipment				
e Other				

Total. Add lines 1a through 1e (Column (d) must equal Form 990, Part X, column (B), line 10c) _____

Part VII Investments - Other Securities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11b See Form 990, Part X, line 12

(a) Description of security or category (including name of security)	(b) Book value	(c) Method of valuation Cost or end-of-year market value
(1) Financial derivatives		
(2) Closely-held equity interests		
(3) Other		
(A)		
(B)		
(C)		
(D)		
(E)		
(F)		
(G)		
(H)		
Total. (Column (b) must equal Form 990, Part X, col (B) line 12.) ▶		

Part VIII Investments - Program Related.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11c. See Form 990, Part X, line 13.

(a) Description of investment	(b) Book value	(c) Method of valuation Cost or end-of-year market value
(1)		
(2)		
(3)		
(4)		
(5)		
(6)		
(7)		
(8)		
(9)		
Total. (Column (b) must equal Form 990, Part X, col (B) line 13.) ▶		

Part IX Other Assets.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11d. See Form 990, Part X, line 15

(a) Description	(b) Book value
(1)	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col (B) line 15.) ▶	

Part X Other Liabilities.

Complete if the organization answered "Yes" on Form 990, Part IV, line 11e or 11f See Form 990, Part X, line 25

1. (a) Description of liability	(b) Book value
(1) Federal income taxes	
(2)	
(3)	
(4)	
(5)	
(6)	
(7)	
(8)	
(9)	
Total. (Column (b) must equal Form 990, Part X, col (B) line 25.) ▶	

2. Liability for uncertain tax positions In Part XIII, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48 (ASC 740) Check here if the text of the footnote has been provided in Part XIII

Part XI Reconciliation of Revenue per Audited Financial Statements With Revenue per Return.
 Complete if the organization answered "Yes" on Form 990, Part IV, line 12a.

1 Total revenue, gains, and other support per audited financial statements		1
2 Amounts included on line 1 but not on Form 990, Part VIII, line 12		
a Net unrealized gains (losses) on investments	2a	2e
b Donated services and use of facilities	2b	
c Recoveries of prior year grants	2c	
d Other (Describe in Part XIII)	2d	
e Add lines 2a through 2d		
3 Subtract line 2e from line 1		3
4 Amounts included on Form 990, Part VIII, line 12, but not on line 1		
a Investment expenses not included on Form 990, Part VIII, line 7b	4a	4c
b Other (Describe in Part XIII)	4b	
c Add lines 4a and 4b		
5 Total revenue. Add lines 3 and 4c. (This must equal Form 990, Part I, line 12)		5

Part XII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return.
 Complete if the organization answered "Yes" on Form 990, Part IV, line 12a

1 Total expenses and losses per audited financial statements		1
2 Amounts included on line 1 but not on Form 990, Part IX, line 25		
a Donated services and use of facilities	2a	2e
b Prior year adjustments	2b	
c Other losses	2c	
d Other (Describe in Part XIII)	2d	
e Add lines 2a through 2d		
3 Subtract line 2e from line 1		3
4 Amounts included on Form 990, Part IX, line 25, but not on line 1		
a Investment expenses not included on Form 990, Part VIII, line 7b	4a	4c
b Other (Describe in Part XIII)	4b	
c Add lines 4a and 4b		
5 Total expenses. Add lines 3 and 4c. (This must equal Form 990, Part I, line 18)		5

Part XIII Supplemental Information.

Provide the descriptions required for Part II, lines 3, 5, and 9, Part III, lines 1a and 4, Part IV, lines 1b and 2b, Part V, line 4, Part X, line 2, Part XI, lines 2d and 4b, and Part XII, lines 2d and 4b. Also complete this part to provide any additional information

SEE PAGE 5

Part XIII Supplemental Information (continued)

SCHEDULE D, PART V, LINE 4

TGEN FOUNDATION CLASSIFIES AS PERMANENTLY RESTRICTED NET ASSETS (1) THE ORIGINAL VALUE OF THE GIFT DONATED TO THE PERMANENT ENDOWMENT, (2) THE ORIGINAL VALUE OF SUBSEQUENT GIFTS DONATED TO THE PERMANENT ENDOWMENT, AND (3) ACCUMULATIONS TO THE PERMANENT ENDOWMENT MADE IN ACCORDANCE WITH THE DIRECTION OF THE APPLICABLE DONOR GIFT INSTRUMENT.

TGEN FOUNDATION HAS A TEMPORARILY RESTRICTED ASSET WHICH HAS BEEN DESIGNED TO SUPPORT A SUMMER INTERN EACH YEAR AT TGEN. TGEN FOUNDATIONS'S POLICY FOR APPROPRIATING THE DISTRIBUTION OF ITS SUMMER INTERNSHIP PROGRAM ENDOWMENT HAS BEEN DESIGNED TO SUPPORT A GRANT TO TGEN FOR AN INTERN EACH YEAR FOR 20 YEARS. THE FOUNDATION CONSIDERED THE LONG-TERM EXPECTED RETURN ON ITS ENDOWMENT.

TGEN FOUNDATION HAS A RESTRICTED ASSET WHICH ALLOWS THEM TO USE ANY INVESTMENT INCOME FOR OPERATING EXPENSES.

SCHEDULE D, PART X, LINE 2

TGEN AND THE FOUNDATION ARE EXEMPT FROM INCOME TAXES UNDER SECTION 501(C)(3) OF THE U.S. INTERNAL REVENUE CODE. TGEN AND THE FOUNDATION ARE EXEMPT FROM ARIZONA CORPORATE INCOME TAX UNDER SECTION 43-1201(A) OF THE ARIZONA REVISED STATUTES (A.R.S.) ACCORDINGLY, NO PROVISION FOR INCOME TAX IS INCLUDED IN THE ACCOMPANYING CONSOLIDATED FINANCIAL STATEMENTS.

TGEN AND THE FOUNDATION HAVE NO SIGNIFICANT UNCERTAIN TAX POSITIONS OR TAX LIABILITY FOR TAX BENEFITS, INTEREST, OR PENALTIES ACCRUED AT SEPTEMBER 30, 2017.

**SCHEDULE I
(Form 990)**

**Grants and Other Assistance to Organizations,
Governments, and Individuals in the United States**

OMB No 1545-0047

2017

**Open to Public
Inspection**

Complete if the organization answered "Yes" on Form 990, Part IV, line 21 or 22.
▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for the latest information.

Department of the Treasury
Internal Revenue Service

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
FOUNDATION

Employer identification number
33-1092191

Part I General Information on Grants and Assistance

- 1 Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance? Yes No
- 2 Describe in Part IV the organization's procedures for monitoring the use of grant funds in the United States

Part II Grants and Other Assistance to Domestic Organizations and Domestic Governments. Complete if the organization answered "Yes" on Form 990, Part IV, line 21, for any recipient that received more than \$5,000. Part II can be duplicated if additional space is needed

1 (a) Name and address of organization or government	(b) EIN	(c) IRC section (if applicable)	(d) Amount of cash grant	(e) Amount of non-cash assistance	(f) Method of valuation (book, FMV, appraisal, other)	(g) Description of non-cash assistance	(h) Purpose of grant or assistance
(1) TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 445 N 5TH ST, SUITE 600 PHOENIX, AZ 85004	75-3065445	501 (C) (3)	3,532,132				FUNDRAISING FOR TGEN
(2)							
(3)							
(4)							
(5)							
(6)							
(7)							
(8)							
(9)							
(10)							
(11)							
(12)							

- 2 Enter total number of section 501(c)(3) and government organizations listed in the line 1 table 1.
- 3 Enter total number of other organizations listed in the line 1 table

For Paperwork Reduction Act Notice, see the Instructions for Form 990. Schedule I (Form 990) (2017)

Part III Grants and Other Assistance to Domestic Individuals. Complete if the organization answered "Yes" on Form 990, Part IV, line 22. Part III can be duplicated if additional space is needed.

	(a) Type of grant or assistance	(b) Number of recipients	(c) Amount of cash grant	(d) Amount of non-cash assistance	(e) Method of valuation (book, FMV, appraisal, other)	(f) Description of non-cash assistance
1						
2						
3						
4						
5						
6						
7						

Part IV Supplemental Information. Provide the information required in Part I, line 2, Part III, column (b), and any other additional information.

SCHEDULE I, PART I, LINE 2

THE FOUNDATION IS ORGANIZED EXCLUSIVELY TO BENEFIT TGEN, A RELATED 501(C)(3) TAX-EXEMPT ORGANIZATION, BY SUPPORTING TGEN'S FUNDRAISING AND DEVELOPMENT FUNCTIONS. THE FOUNDATION RELIES UPON THE GOVERNANCE PRACTICES OF TGEN TO MONITOR USE OF GRANT FUNDS.

**SCHEDULE M
(Form 990)**

Noncash Contributions

OMB No 1545-0047

Department of the Treasury
Internal Revenue Service

- ▶ Complete if the organizations answered "Yes" on Form 990, Part IV, lines 29 or 30.
- ▶ Attach to Form 990.
- ▶ Go to www.irs.gov/Form990 for the latest information.

2017

Open to Public Inspection

Name of the organization **THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE**
FOUNDATION

Employer identification number
33-1092191

Part I Types of Property

	(a) Check if applicable	(b) Number of contributions or items contributed	(c) Noncash contribution amounts reported on Form 990, Part VIII, line 1g	(d) Method of determining noncash contribution amounts
1 Art - Works of art				
2 Art - Historical treasures				
3 Art - Fractional interests				
4 Books and publications				
5 Clothing and household goods				
6 Cars and other vehicles	X	1.	60,000.	COST
7 Boats and planes				
8 Intellectual property				
9 Securities - Publicly traded				
10 Securities - Closely held stock				
11 Securities - Partnership, LLC, or trust interests				
12 Securities - Miscellaneous				
13 Qualified conservation contribution - Historic structures				
14 Qualified conservation contribution - Other				
15 Real estate - Residential				
16 Real estate - Commercial				
17 Real estate - Other				
18 Collectibles				
19 Food inventory				
20 Drugs and medical supplies				
21 Taxidermy				
22 Historical artifacts				
23 Scientific specimens				
24 Archeological artifacts				
25 Other ▶ ()				
26 Other ▶ ()				
27 Other ▶ ()				
28 Other ▶ ()				

29 Number of Forms 8283 received by the organization during the tax year for contributions for which the organization completed Form 8283, Part IV, Donee Acknowledgement 29 1.

		Yes	No
30a During the year, did the organization receive by contribution any property reported in Part I, lines 1 through 28, that it must hold for at least three years from the date of the initial contribution, and which isn't required to be used for exempt purposes for the entire holding period?	30a		X
b If "Yes," describe the arrangement in Part II			
31 Does the organization have a gift acceptance policy that requires the review of any nonstandard contributions?	31	X	
32a Does the organization hire or use third parties or related organizations to solicit, process, or sell noncash contributions?	32a	X	
b If "Yes," describe in Part II			
33 If the organization didn't report an amount in column (c) for a type of property for which column (a) is checked, describe in Part II			

For Paperwork Reduction Act Notice, see the Instructions for Form 990

Schedule M (Form 990) (2017)

Part II **Supplemental Information.** Provide the information required by Part I, lines 30b, 32b, and 33, and whether the organization is reporting in Part I, column (b), the number of contributions, the number of items received, or a combination of both. Also complete this part for any additional information.

SCHEDULE M, PART I

THE ORGANIZATION IS REPORTING IN PART I, COLUMN (B) THE NUMBER OF CONTRIBUTIONS RECEIVED.

SCHEDULE M, PART I, LINE 32

DONATED VEHICLES ARE PUT ON CONSIGNMENT WITH AN AUCTION COMPANY. VEHICLES ARE ENTERED INTO THE AUCTION WITHOUT A RESERVE. CONSIGNMENT FEES ARE WAIVED FOR CHARITY VEHICLES AND BOTH THE SELLER COMMISSION AND BUYERS PREMIUM ARE ALSO WAIVED.

**SCHEDULE O
(Form 990 or 990-EZ)**

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990 or 990-EZ

Complete to provide information for responses to specific questions on
Form 990 or 990-EZ or to provide any additional information.

▶ Attach to Form 990 or 990-EZ.

▶ Information about Schedule O (Form 990 or 990-EZ) and its instructions is at www.irs.gov/form990

OMB No 1545-0047

2017

**Open to Public
Inspection**

Name of the organization FOUNDATION	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	Employer identification number 33-1092191
--	---	--

FORM 990, PART III, LINE 4A

THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION RAISES FUNDS FOR THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE ("TGEN"). THE PROGRAM SERVICE ACCOMPLISHMENTS OF TGEN ARE LISTED BELOW:

SUMMARY OF 2017 ACTIVITIES

TECHNOLOGICAL ADVANCES HAVE CREATED AN INCREASED OPPORTUNITY FOR CLINICAL SCIENCE TO COME ALONGSIDE CLINICAL CARE TOWARD IMPROVING THE HEALTH AND TREATMENT OF INDIVIDUALS AND POPULATIONS. AT TGEN, WE ARE PIONEERS IN DECIPHERING THE STORY A PERSON'S GENOME HAS TO TELL. FOR INDIVIDUALS FACED WITH A CANCER DIAGNOSIS, OUR SCIENTISTS AND CLINICIANS HAVE THE ABILITY TO LET A PATIENT'S GENOME REVEAL ITS UNIQUENESS IN WAYS THAT ARE BOTH POWERFUL AND TRANSFORMATIVE, ESPECIALLY WHEN IT COMES TO TREATING DISEASE IN A PRECISE AND INDIVIDUAL MANNER.

AT TGEN, WE ARE SETTING A NEW MEDICAL STANDARD WHERE THE FUTURE OF CANCER MEDICINE IS HAPPENING NOW. TGEN HAS HAD AN IMPORTANT AND HIGHLY POSITIVE IMPACT IN UNDERSTANDING THE MOLECULAR DRIVERS IN CANCER, BUT MORE IMPORTANTLY, HAS BEEN AMONG THE WORLD'S LEADERS IN APPLYING THIS KNOWLEDGE TOWARD THE TREATMENT OF CANCER PATIENTS.

JUNE 2017 MARKED 15 YEARS SINCE TGEN'S INCEPTION. IN THAT TIME, TGEN HAS LED EFFORTS IN BRINGING PRECISION MEDICINE TO THE PATIENT BEDSIDE,

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

CONTINUES TO HAVE A POSITIVE IMPACT ON ARIZONA'S ECONOMY, AND PROVIDE PATIENTS WITH NEW HOPE AND ANSWERS.

TGEN'S AFFILIATION WITH CITY OF HOPE, ANNOUNCED IN LATE 2016, CONTINUED TO GAIN TRACTION THROUGHOUT THE YEAR. AMONG THE FIRST MAJOR RESULTS WAS THE JOINT RECRUITMENT OF DR. SUNIL SHARMA, WHO HOLDS APPOINTMENTS AT TGEN, HONORHEALTH AND CITY OF HOPE. DR. SHARMA IS A CELEBRATED CANCER INVESTIGATOR RESPONSIBLE FOR HELPING DEVELOP SOME OF THE WORLD'S MOST ADVANCED ANTI-CANCER AGENTS. HE MOST RECENTLY WAS DEPUTY DIRECTOR OF HUNTSMAN CANCER INSTITUTE (HCI) IN SALT LAKE CITY, UTAH. PREVIOUSLY HE SERVED AS SENIOR DIRECTOR OF CLINICAL RESEARCH AND DIRECTOR OF THE CENTER FOR INVESTIGATIONAL THERAPEUTICS AT HCI, WHERE HE ALSO HELD A JON AND KAREN HUNTSMAN PRESIDENTIAL PROFESSORSHIP IN CANCER RESEARCH AND TAUGHT AT THE UNIVERSITY OF UTAH SCHOOL OF MEDICINE.

WORKING WITH COLLABORATORS, TGEN MADE SIGNIFICANT ADVANCES IN BRAIN CANCER AND ALZHEIMER'S DISEASE.

WORKING WITH THE UNIVERSITY OF NORTH CAROLINA LINEBERGER COMPREHENSIVE CANCER CENTER, TGEN RESEARCHERS HAVE DISCOVERED NEW INSIGHTS INTO THE EVOLUTION OF GLIOBLASTOMA, AND HOW TO POTENTIALLY COMBAT THIS AGGRESSIVE BRAIN CANCER, THANKS TO CONTINUED FUNDING FROM THE BEN & CATHERINE IVY FOUNDATION.

WORKING WITH ARIZONA STATE UNIVERSITY, WITH FUNDING FROM THE ARIZONA

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

ALZHEIMER'S CONSORTIUM AND THE ARIZONA BIOMEDICAL RESEARCH COMMISSION, WE RECENTLY COMPLETED STUDIES THAT SHOWED BOTH A BIOLOGICAL PATHWAY THAT LEADS TO NEURONAL LOSS, AND ALSO IDENTIFIED THE ORIGIN OF A GENE WHOSE ALTERED EXPRESSION MAY CONTRIBUTE TO THIS MEMORY-ROBBING DISEASE.

IN THE MEANTIME, THE FDA CLEARED A NEW RAPID AND ACCURATE TEST FOR VALLEY FEVER. THE TEST WILL BE MARKETED BY DXNA LLC, A FIRM BASED IN ST. GEORGE, UTAH, WHICH LICENSED THE TECHNOLOGY DEVELOPED BY TGEN NORTH IN CONJUNCTION WITH NORTHERN ARIZONA UNIVERSITY.

OUR PARTNERSHIP WITH BAYLOR SCOTT & WHITE RESEARCH INSTITUTE (BSWRI) IN DALLAS ALSO PROGRESSED SUBSTANTIALLY WITH THE COMPLETION OF NUMEROUS RESEARCH AGREEMENTS, AND THE ANNOUNCEMENT IN DECEMBER THAT TGEN AND BAYLOR WOULD LEAD A 5-YEAR, \$5.13 MILLION EFFORT FUNDED BY THE NATIONAL CANCER INSTITUTE TO DEVELOP METHODS OF EARLY DETECTION IN PANCREATIC CANCER.

IN ADDITION, THE FOLLOWING OVERVIEW PROVIDES A SNAPSHOT OF RECENT PROGRESS IN GRANT SUPPORT, OUTCOMES AND PROGRESS, CLINICAL TRIALS, PATENTS AND LICENSES, PEER REVIEWED PUBLICATIONS AND PRESENTATIONS, EMPLOYMENT, EDUCATION AND OUTREACH, AND MEDIA.

GRANT SUPPORT

IN ADDITION TO PHILANTHROPIC DONATIONS AND RESEARCH CONTRACTS, GRANTS ARE AN IMPORTANT FUNDING SOURCE FOR RESEARCH. FROM JANUARY 1 THROUGH

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

SEPTEMBER 30, TGEN INVESTIGATORS SUBMITTED 54 GRANTS TOTALING \$37,388,389. DURING THIS PERIOD, TGEN WAS AWARDED 15 GRANTS, TOTALING \$3,467,701.

A SELECTION OF AWARDS INCLUDES:

- (A) FOUR-YEAR GRANT FROM THE DEFENSE THREAT REDUCTION AGENCY (DTRA) TOTALING \$919,694 TO DR. DAVID ENGELTHALER FOR THE IDENTIFICATION AND CHARACTERIZATION OF ANTIMICROBIAL SUSCEPTIBILITY MARKERS IN BURHOLDERIA PSEUDOMALLIE.
- (B) ONE-YEAR GRANT FROM THE U.S. CENTERS FOR DISEASE CONTROL (CDC) TOTALING \$109,504 TO DR. DAVID ENGELTHALER TO EXAMINE HOMOLOGOUS AND NON-HOMOLOGOUS RECOMBINATION IN DISEASE OUTBREAK ANALYSIS.
- (C) THREE-YEAR GRANT FROM THE DEPARTMENT OF DEFENSE TOTALING \$661,015 TO DR. VINODH NARAYANAN FOR THE STUDY OF PHENOTYPIC VARIABILITY AMONG PATIENTS WITH TUBEROUS SCLEROSIS COMPLEX.
- (D) THREE-YEAR GRANT FROM UNIVERSITY OF NORTH CAROLINA AND THE NATIONAL INSTITUTE OF HEALTH TOTALING \$619,879 TO DR. MICHAEL BERENS TO ADVANCE CREDENTIALING MURINE MODELS FOR GLIOBLASTOMA PRECLINICAL DRUG DEVELOPMENT.
- (E) TWO-YEAR GRANT FROM THE BILL & MELINDA GATES FOUNDATION TOTALING \$600,000 TO DR. DAVE ENGELTHALER FOR TUBERCULOSIS SEQUENCING.
- (F) ONE-YEAR GRANT FROM THE OHIO STATE UNIVERSITY AND THE NATIONAL INSTITUTE OF HEALTH TOTALING \$245,334 TO DR. JEFFREY TRENT FOR IMMUNOGENOMIC PROFILING OF CANINE MELANOMA AND OSTEOSARCOMA.
- (G) FIVE-YEAR GRANT FROM BANNER HEALTH AND THE NATIONAL INSTITUTE OF

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

HEALTH TOTALING \$113,365 TO DR. MATTHEW HUENTELMAN FOR THE ARIZONA ALZHEIMER'S DISEASE CORE CENTER.

(H) THREE-YEAR GRANT FROM THE HELIOS EDUCATION FOUNDATION OF \$346,000 TO FUND A NEW TGEN PROGRAM FOR HIGH SCHOOL STUDENTS.

OUTCOMES AND PROGRESS

IN 2017, TGEN ADVANCED A SERIES OF INNOVATIVE RESEARCH INITIATIVES THAT YIELDED NUMEROUS SCIENTIFIC DISCOVERIES (A GOOD NUMBER WITH POTENTIAL CLINICAL APPLICATION), ESTABLISHED NATIONAL AND INTERNATIONAL COLLABORATIONS, AND LED NEW AND EXCITING CLINICAL TRIALS WITH PROMISING RESULTS. NOTABLE ARE:

(A) A STUDY LED BY SCIENTISTS AT TGEN IDENTIFIED "A POTENT INHIBITORY COMPOUND" IN THE ELUSIVE HUNT FOR AN IMPROVED TREATMENT AGAINST GLIOBLASTOMA, THE MOST COMMON AND DEADLY TYPE OF ADULT BRAIN CANCER. AURINTRICARBOXYLIC ACID (ATA) IS A CHEMICAL COMPOUND THAT IN LABORATORY TESTS WAS SHOWN TO BLOCK THE CHEMICAL CASCADE THAT OTHERWISE ALLOWS GLIOBLASTOMA CELLS TO INVADE NORMAL BRAIN TISSUE AND RESIST BOTH CHEMO AND RADIATION THERAPY. THE FINDINGS OF THIS STUDY COULD REPRESENT A BREAKTHROUGH IN OUR EFFORTS TO FIND AN EFFECTIVE LONG-TERM TREATMENT AGAINST GLIOBLASTOMA MULTIFORME (GBM). THE PUBLISHED RESULTS APPEARED IN THE SCIENTIFIC JOURNAL ONCOTARGET.

(B) RESEARCHERS AT TGEN IDENTIFIED A GENOMIC MUTATION THAT CAUSES

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

PHYSICAL ABNORMALITIES AND DEVELOPMENTAL DELAYS IN CHILDREN. WHOLE GENOME SEQUENCING ANALYSIS OF A SIX-YEAR-OLD BOY REVEALED A NOVEL MUTATION THAT AFFECTS A PROTEIN KNOWN AS CASK, WHICH IS KEY TO BRAIN DEVELOPMENT AND THE SIGNALS TRANSMITTED BY BRAIN CELLS, OR NEURONS. IDENTIFYING THIS NEW CASK MUTATION ADDS TO THE SCIENTIFIC UNDERSTANDING OF HOW THESE MULTIFACETED DISORDERS OCCUR, AND PROVIDES INSIGHT INTO HOW THEY MIGHT BE TREATED IN THE FUTURE. THE RESULTS APPEARED IN THE AMERICAN JOURNAL OF MEDICAL GENETICS. THE CHILD INVOLVED IN THIS STUDY WAS SEEN AT TGEN'S CENTER FOR RARE CHILDHOOD DISORDERS, WHICH HELPS FAMILIES IDENTIFY THE GENETIC SOURCE OF THEIR CHILDREN'S MEDICAL SYMPTOMS.

(C) A THREE-YEAR STUDY OF THE ARIZONA STATE UNIVERSITY FOOTBALL PROGRAM ALLOWED RESEARCHERS AT TGEN TO CREATE THE LARGEST DATASET TO DATE OF EXTRACELLULAR SMALL RNAs, WHICH ARE POTENTIAL BIOMARKERS FOR DIAGNOSING MEDICAL CONDITIONS, INCLUDING CONCUSSIONS. THE STUDY AMASSED A COLLECTION OF BIOMARKERS FROM THE ASU STUDENT-ATHLETES' BIOFLUIDS: BLOOD, URINE AND SALIVA. A PORTION OF THAT INFORMATION WILL BE USED WITH DATA FROM HELMET SENSORS THAT RECORDED THE NUMBER, INTENSITY AND DIRECTION OF HEAD IMPACTS DURING GAMES AND PRACTICES FROM THE 2013-2016 FOOTBALL TEAMS. TGEN RESEARCHERS ARE USING THAT COMBINED DATA TO POTENTIALLY DEVELOP NEW DIAGNOSTIC AND THERAPEUTIC TOOLS. DETAILS OF THE DATASET WERE PUBLISHED IN SCIENTIFIC REPORTS AND AN ON-LINE OPEN-ACCESS JOURNAL OF THE NATURE PUBLISHING GROUP. BECAUSE THE DATA IS BEING PUBLISHED IN AN OPEN ACCESS JOURNAL, THEY ARE AVAILABLE TO AID OTHER RESEARCHERS STUDYING HOW TO DEVELOP TESTS FOR THE DETECTION AND EXTENT OF INJURIES INVOLVING

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

EVERYTHING FROM AUTOMOBILE ACCIDENTS TO BATTLEFIELD EXPLOSIONS.

(D) IN EARLY APRIL, A TEAM OF RESEARCHERS REPORTED A SIGNIFICANT GENETIC ASSOCIATION LINKED TO AN AGGRESSIVE FORM OF MELANOMA IN A STUDY PUBLISHED IN THE JOURNAL GENOME RESEARCH. ACRAL LENTIGINOUS MELANOMA, OR ALM, IS AN UNCOMMON TYPE OF MELANOMA THAT TYPICALLY OCCURS ON THE PALMS AND SOLES AND IS OFTEN DIFFICULT TO TREAT. LED BY INVESTIGATORS AT TGEN, IN COLLABORATION WITH VANDERBILT UNIVERSITY MEDICAL CENTER, MEMORIAL SLOAN KETTERING CANCER CENTER, AND MAYO CLINIC, RESEARCHERS IDENTIFIED A PROTEIN TARGET THAT OPENS A WINDOW INTO THE DISEASE AND MAY AID IN DIAGNOSIS AND, ONE DAY, LEAD TO IMPROVED TREATMENTS. THE RESEARCHERS SEQUENCED SAMPLES FROM 34 PATIENTS WITH ALM AND FOUND SIGNIFICANT EVIDENCE THAT INHIBITING A PROTEIN CALLED TERT MAY BE "AN EFFECTIVE APPROACH" TO DESTROYING ALM CELLS. THE FINDINGS PROVIDE INSIGHT INTO THE ROLE TERT PLAYS IN THE FORMATION OF ALM, AND REVEAL PRELIMINARY EVIDENCE THAT INHIBITING TERT HAS A DEADLY EFFECT ON ALM CANCER CELLS. IN LABORATORY EXPERIMENTS, MORE THAN 75 PERCENT OF ALM CANCER CELLS WERE AFFECTED, FOLLOWING 72 HOURS OF EXPOSURE TO A DRUG THAT INHIBITS TERT.

(E) RESEARCHERS LED BY ARIZONA STATE UNIVERSITY (ASU) AND TGEN IDENTIFIED ALTERED EXPRESSION OF A GENE CALLED ANK1, WHICH ONLY RECENTLY HAS BEEN ASSOCIATED WITH MEMORY ROBBING ALZHEIMER'S DISEASE, IN SPECIFIC CELLS IN THE BRAIN. USING AN EXTREMELY PRECISE METHOD OF ISOLATING CELLS CALLED "LASER CAPTURE MICRODISSECTION," RESEARCHERS LOOKED AT THREE SPECIFIC CELL TYPES - MICROGLIA, ASTROCYTES AND NEURONS - IN THE BRAIN TISSUE OF INDIVIDUALS WITH A PATHOLOGICAL DIAGNOSIS OF ALZHEIMER'S DISEASE, AND

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

COMPARED THEM TO BRAIN SAMPLES FROM HEALTHY INDIVIDUALS AND THOSE WITH PARKINSON'S DISEASE. FOLLOWING SEQUENCING OF EACH OF THESE CELL TYPES, THE ASU-TGEN LED TEAM FOUND THAT ALTERED ANK1 EXPRESSION ORIGINATES IN MICROGLIA, A TYPE OF IMMUNE CELL FOUND IN THE BRAIN AND CENTRAL NERVOUS SYSTEM. ALTHOUGH PREVIOUS GENETIC AND EPIGENETIC-WIDE ASSOCIATION STUDIES HAD SHOWN A SIGNIFICANT ASSOCIATION BETWEEN ANK1 AND AD, THEY WERE UNABLE TO IDENTIFY THE CLASS OF CELLS THAT MAY BE RESPONSIBLE FOR SUCH ASSOCIATION BECAUSE OF THE USE OF BRAIN HOMOGENATES. THE RESULTS PROVIDE EVIDENCE THAT MICROGLIA ARE THE SOURCE OF THE PREVIOUSLY OBSERVED DIFFERENTIAL EXPRESSION PATTERNS IN THE ANK1 GENE IN ALZHEIMER'S DISEASE. THE STUDY APPEARED IN THE SCIENTIFIC JOURNAL PLOS ONE.

(F) A STUDY DETAILING HOW BLOCKING NERVE GROWTH FACTOR KEEPS PANCREATIC CANCER CELLS FROM INVADING SURROUNDING NERVES MAY LEAD TO POTENTIAL DRUG TARGETS TO REDUCE PAIN IN PANCREATIC CANCER PATIENTS. TGEN RESEARCHERS HAVE FOUND THAT THE NERVE GROWTH FACTOR (NGF), A NEUROTROPHIC FACTOR, AND ITS RECEPTOR TRKA ARE ASSOCIATED WITH PERINEURAL INVASION (PNI), WHICH IS THE ABILITY OF PANCREATIC CANCER CELLS TO INVADE SURROUNDING NERVES. BLOCKING THE NGF SIGNALING THROUGH INHIBITORS OF NGF AND TRKA REDUCES THE POTENTIAL OF PANCREATIC CANCER CELLS TO MIGRATE TOWARDS THE SURROUNDING NERVES. THE STUDY RESULTS APPEARED IN PLOS ONE.

(G) A STUDY PUBLISHED BY ARIZONA STATE UNIVERSITY-BANNER HEALTH NEUROSCIENTIST DR. SALVATORE ODDO AND COLLEAGUES FROM TGEN - AS WELL AS UC, IRVINE AND MOUNT SINAI IN NEW YORK - HAVE IDENTIFIED A NEW WAY FOR

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

BRAIN CELLS TO BECOME FATED TO DIE DURING ALZHEIMER'S DISEASES. THE RESEARCHERS FOUND THE FIRST EVIDENCE THAT THE ACTIVATION OF A BIOLOGICAL PATHWAY CALLED NECROPTOSIS, WHICH CAUSES NEURONAL LOSS, IS CLOSELY LINKED WITH ALZHEIMER'S SEVERITY, COGNITIVE DECLINE AND EXTREME LOSS OF TISSUE AND BRAIN WEIGHT THAT ARE ALL ADVANCED HALLMARKS OF THE DISEASE. IT IS ANTICIPATED THAT THE FINDINGS WILL SPUR A NEW AREA OF ALZHEIMER'S DISEASE RESEARCH FOCUSED ON FURTHER DETAILING THE ROLE OF NECROPTOSIS AND DEVELOPING NEW THERAPEUTIC STRATEGIES AIMED AT BLOCKING THE NECROPTOSIS PATHWAY. THE FINDINGS APPEAR IN THE ADVANCED ON-LINE EDITION OF NATURE NEUROSCIENCE.

CLINICAL TRIALS

THE VIRGINIA G. PIPER CANCER CENTER (VGPC) CLINICAL TRIALS PROGRAM AT HONORHEALTH PROVIDES A DIRECT CLINICAL RESEARCH SITE FOR TGEN. TGEN PHYSICIAN-IN-CHIEF, DANIEL VON HOFF, M.D., F.A.C.P., SERVES AS CHIEF SCIENTIFIC OFFICER. PROGRAM CLINICIANS FOCUS ON CLINICAL TRIALS WITH TARGETED AGENTS AND GENOMIC-BASED INDIVIDUALIZED THERAPY. THEIR INITIAL FOCUS ON CANCER ALLOWS THE UNIQUE OPPORTUNITY FOR TGEN TO TRANSITION ITS LABORATORY-BASED RESEARCH TO PATIENT CARE CENTERED ON INDIVIDUALIZED THERAPY.

CLINICALLY, WE CONTINUE TO LAUNCH INNOVATIVE PROGRAMS THAT EXPAND THE BOUNDARIES OF SCIENCE AND MEDICINE. CURRENT INITIATIVES INCLUDE:

(1) MULTIPLE CLINICAL TRIALS UNDERWAY TO INVESTIGATE NEW CHEMICAL AGENTS FOR A VARIETY OF TUMOR TYPES IN DIFFERENT CANCERS.

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

(2) INCORPORATION OF MODERN TOOLS TO IDENTIFY PATIENTS' GENOMIC CHARACTERISTICS THAT COULD LEAD TO A MORE TARGETED APPROACH.

PATENTS AND LICENSES

FROM JANUARY 1 THROUGH SEPTEMBER 30, TGEN WAS ISSUED 8 PATENTS AND FILED 16 PATENT APPLICATIONS ON TGEN-GENERATED RESEARCH.

PEER-REVIEWED LABORATORY RESEARCH PUBLICATIONS AND PRESENTATIONS TGEN EXPERIENCED SIGNIFICANT SCIENTIFIC AND MEDICAL PROGRESS ACROSS MULTIPLE AREAS OF THE INSTITUTE, MANY OF WHICH REACHED NEW HEIGHTS AND FORGED THE POTENTIAL FOR SIGNIFICANTLY GREATER ACHIEVEMENTS IN THE FUTURE.

BUILDING ON OUR RECENT EFFORTS AROUND PRECISION MEDICINE, WE CONTINUE TO PROVIDE PATIENTS WITH NEW HOPE AND ANSWERS. TGEN RESEARCHERS AND CLINICIANS, WORKING HAND-IN-HAND WITH A MULTITUDE OF COLLABORATORS FROM ACROSS THE NATION AND AROUND THE WORLD, ARE FINDING WAYS AT EVERY LEVEL TO MOVE FORWARD TOGETHER, ESPECIALLY IN IMMUNOTHERAPY AND GENOMICS, TO RAPIDLY GAIN NEW INSIGHTS AND EXPAND OPPORTUNITIES FOR THE DESIGN OF NEW INTERVENTIONS.

IN 2017, TGEN RESEARCHERS PUBLISHED THEIR RESEARCH RESULTS EXTENSIVELY IN NUMEROUS SCHOLARLY PEER-REVIEWED ACADEMIC JOURNALS AND THROUGH PRESENTATIONS AT LEADING NATIONAL AND INTERNATIONAL CONFERENCES. THESE INCLUDE PUBLICATION IN LEADING SCIENTIFIC JOURNALS SUCH AS AMERICAN

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

JOURNAL OF HUMAN GENETICS, NATURE, NATURE COMMUNICATIONS, NATURE GENETICS, CANCER DISCOVERY, CLINICAL CANCER RESEARCH, MBIO, DIABETES, NEURO ONCOLOGY.

2017 SELECT PUBLICATIONS

-BENYAMIN B, MAIHOFFER AX, SCHORK AJ, HAMILTON BA, RAO F, SCHMID-SCHONBEIN GW, ZHANG K, MAHATA M, STRIDSBERG M, SCHORK NJ, BISWAS N, HOOK VY, WEI Z, MONTGOMERY GW, MARTIN NG, NIEVERGELT CM, WHITFIELD JB, O'CONNOR DT.

IDENTIFICATION OF NOVEL LOCI AFFECTING CIRCULATING CHROMOGRANINS AND RELATED PEPTIDES. HUM MOL GENET. 2017 JAN 1;26(1):233-242.

-CHEWAPREECHA C, HOLDEN MT, VEKALA M, VALIMAKI N, YANG Z, HARRIS SR, MATHER AE, TUANYOK A, DE SMET B, LE HELLO S, BIZET C, MAYO M, WUTHIEKANUN V, LIMMATHUROTSAKUL D, PHETSOUVANH R, SPRATT BG, CORANDER J, KEIM P, DOUGAN G, DANCE DA, CURRIE BJ, PARKHILL J, PEACOCK SJ. GLOBAL AND REGIONAL DISSEMINATION AND EVOLUTION OF BURKHOLDERIA PSEUDOMALLEI. NAT MICROBIOL. 2017 JAN 23;2:16263.

-GUZMÁN YF, RAMSEY K, STOLZ JR, CRAIG DW, HUENTELMAN MJ, NARAYANAN V, SWANSON GT. A GAIN-OF-FUNCTION MUTATION IN THE GRIK2 GENE CAUSES NEURODEVELOPMENTAL DEFICITS. NEUROL GENET. 2017 JAN 31;3(1):E129.

-ARORA N, ALSAIED O, DAUER P, MAJUMDER K, MODI S, GIRI B, DUDEJA V, BANERJEE S, VON HOFF D, SALUJA A. DOWNREGULATION OF SPI BY MINNELIDE LEADS TO DECREASE IN HSP70 AND DECREASE IN TUMOR BURDEN OF GASTRIC CANCER. PLOS ONE. 2017 FEB 13;12(2):E0171827.

-ROOS A, DHRUV HD, MATHEWS IT, INGE LJ, TUNCALI S, HARTMAN LK, CHOW D, MILLARD N, YIN HH, KLOSS J, LOFTUS JC, WINKLES JA, BERENS ME, TRAN NL. IDENTIFICATION OF AURINTRICARBOXYLIC ACID AS A SELECTIVE INHIBITOR OF THE

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

TWEAK-FN14 SIGNALING PATHWAY IN GLIOBLASTOMA CELLS. ONCOTARGET. 2017 FEB 14;8(7):12234-12246.

-DING KF, FINLAY D, YIN H, HENDRICKS WP, SEREDUK C, KIEFER J, SEKULIC A, LORUSSO PM, VUORI K, TRENT JM, SCHORK NJ. ANALYSIS OF VARIABILITY IN HIGH THROUGHPUT SCREENING DATA: APPLICATIONS TO MELANOMA CELL LINES AND DRUG RESPONSES. ONCOTARGET. 2017 FEB 15. [EPUB AHEAD OF PRINT]

-MATEESCU B, KOWAL EJ, VAN BALKOM BW, BARTEL S, BHATTACHARYYA SN, BUZÁS EI, BUCK AH, DE CANDIA P, CHOW FW, DAS S, DRIEDONKS TA, FERNÁNDEZ-MESSINA L, HADERK F, HILL AF, JONES JC, VAN KEUREN-JENSEN KR, LAI CP, LASSER C, LIEGRO ID, LUNAVAT TR, LORENOWICZ MJ, MAAS SL, MAGER I, MITTELBRUNN M, MOMMA S, MUKHERJEE K, NAWAZ M, PEGTEL DM, PFAFFL MW, SCHIFFELERS RM, TAHARA H, THÉRY C, TOSAR JP, WAUBEN MH, WITWER KW, NOLTE-'T HOEN EN. OBSTACLES AND OPPORTUNITIES IN THE FUNCTIONAL ANALYSIS OF EXTRACELLULAR VESICLE RNA - AN ISEV POSITION PAPER. J EXTRACELL VESICLES. 2017 MAR 7;6(1):1286095.

-YERI A, COURTRIGHT A, REIMAN R, CARLSON E, BEECROFT T, JANSS A, SINIARD A, RICHHOLT R, BALAK C, ROZOWSKY J, KITCHEN R, HUTCHINS E, WINARTA J, MCCOY R, ANASTASI M, KIM S, HUENTELMAN M, VAN KEUREN-JENSEN K. TOTAL EXTRACELLULAR SMALL RNA PROFILES FROM PLASMA, SALIVA, AND URINE OF HEALTHY SUBJECTS. SCI REP. 2017 MAR 17;7:44061.

-ING KF, FINLAY D, YIN H, HENDRICKS WPD, SEREDUK C, KIEFER J, SEKULIC A, LORUSSO PM, VUORI K, TRENT JM, SCHORK NJ. ANALYSIS OF VARIABILITY IN HIGH THROUGHPUT SCREENING DATA: APPLICATIONS TO MELANOMA CELL LINES AND DRUG RESPONSES. ONCOTARGET. 2017 APR 25;8(17):27786-27799.

-LONG T, HICKS M, YU HC, BIGGS WH, KIRKNESS EF, MENNI C, ZIERER J, SMALL

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

KS, MANGINO M, MESSIER H, BREWERTON S, TURPAZ Y, PERKINS BA, EVANS AM,
MILLER LA, GUO L, CASKEY CT, SCHORK NJ, GARNER C, SPECTOR TD, VENTER JC,
TELENTI A. WHOLE-GENOME SEQUENCING IDENTIFIES COMMON-TO-RARE VARIANTS
ASSOCIATED WITH HUMAN BLOOD METABOLITES. NAT GENET. 2017
APR;49(4):568-578.

-TIGCHELAAR S, STREIJGER F, SINHA S, FLIBOTTE S, MANOUCHEHRI N, SO K,
SHORTT K, OKON E, RIZZUTO MA, MALENICA I, COURTRIGHT-LIM A, EISEN A, VAN
KEUREN-JENSEN K, NISLOW C, KWON BK. SERUM MICRORNAS REFLECT INJURY
SEVERITY IN A LARGE ANIMAL MODEL OF THORACIC SPINAL CORD INJURY. SCI REP.
2017 MAY 3;7(1):1376.

-GREENAWALT DM, LIANG WS, SAIF S, JOHNSON J, TODOROV P, DULAK A, ENRIQUEZ
D, HALPERIN R, AHMED A, SAVELIEV V, CARPTEN J, CRAIG D, BARRETT JC,
DOUGHERTY B, ZINDA M, FAWELL S, DRY JR, BYTH K. COMPARATIVE ANALYSIS OF
PRIMARY VERSUS RELAPSE/REFRACTORY DLBCL IDENTIFIES SHIFTS IN MUTATION
SPECTRUM. ONCOTARGET. 2017 JUN 15.

-VISWANATHAN VS, RYAN MJ, DHRUV HD, GILL S, EICHHOFF OM, SEASHORE-LUDLOW
B, KAFFENBERGER SD, EATON JK, SHIMADA K, AGUIRRE AJ, VISWANATHAN SR,
CHATTOPADHYAY S, TAMAYO P, YANG WS, REES MG, CHEN S, BOSKOVIC ZV, JAVAID
S, HUANG C, WU X, TSENG YY, ROIDER EM, GAO D, CLEARY JM, WOLPIN BM,
MESIROV JP, HABER DA, ENGELMAN JA, BOEHM JS, KOTZ JD, HON CS, CHEN Y,
HAHN WC, LEVESQUE MP, DOENCH JG, BERENS ME, SHAMJI AF, CLEMONS PA,
STOCKWELL BR, SCHREIBER SL. DEPENDENCY OF A THERAPY-RESISTANT STATE OF
CANCER CELLS ON A LIPID PEROXIDASE PATHWAY. NATURE. 2017 JUL
27;547(7664):453-457.

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

2017 PRESENTATIONS

-GORDON RESEARCH CONFERENCE - RNA NANOTECHNOLOGY

JANUARY 22-27, VENTURA BEACH, CA

KENDALL VAN KEUREN-JENSEN

EXTRACELLULAR RNAS FOR MONITORING CENTRAL NERVOUS SYSTEM INJURY AND
DISEASE

-2017 PRECISION LBX SUMMIT

JANUARY 30-31, SAN DIEGO, CA

KENDALL VAN KEUREN-JENSEN

USING EXRNA TO MONITOR THE CENTRAL NERVOUS SYSTEM

-KEYSTONE SYMPOSIUM ON EPIGENETICS AND HUMAN DISEASE: PROGRESS FROM
MECHANISMS TO THERAPEUTICS

JANUARY 29 - FEBRUARY 2, SEATTLE, WA

MADELINE KEENEN AND SUWON KIM

ING4 TUMOR SUPPRESSOR IN BREAST CANCER: A CONDITIONAL TRANSCRIPTION
REGULATOR

-29TH FUNGEL GENETICS CONFERENCE

MARCH 14-19, PACIFIC GROVE, CA

DAVID ENGELTHALER

-EPIDEMIOLOGY OF CRYPTOCOCCUS SPP. USING COMPARATIVE GENOMICS

ACMG 2017

MARCH 21-25, PHOENIX, AZ

JESSICA LANG, MEGAN RUSSELL, WILLIAM HENDRICKS, YEMIN WANG, PILAR RAMOS,
HOLLY YIN, JEFFREY KIEFER, ANTHONY KARNEZIS, VICTORIA ZISMANN, BERNARD
WEISSMAN, DAVID HUNTSMAN, JEFFREY TRENT. 142: PATHOGNOMONIC SMARCA4

Name of the organization FOUNDATION	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	Employer identification number 33-1092191
--	---	--

MUTATIONS IN SMALL CELL CARCINOMA OF THE OVARY-HYPERCALCEMIC TYPE

(SCCOHT): DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS.

KERI RAMSEY, VINODH NARAYANAN, CHRIS BALAK, ANA CLAASEN, AMANDA

COURTRIGHT, DAVID CRAIG, MATT DE BOTH, BRITNEY GERALD, MATTHEW

HUENTELMAN, MARCUS NAYMIK, SAMPATH RANGASAMY, RYAN RICHHOLT, MEGAN

RUSSELL, ISABELLE SCHRAUWEN, ASHLEY SINIARD, SZABOLCS SZELINGER, TYLER

IZATT. 254: THE PITFALLS AND TRIUMPHS OF WHOLE EXOME SEQUENCING IN RARE

CHILDHOOD DISORDERS.

-10TH INTERNATIONAL CONFERENCE ON CRYPTOCOCCUS AND CRYPTOCOCCOSIS

MARCH 26-30, FOZ DO IGUACU, BRAZIL

DAVID ENGELTHALER

A PHYLOGENOMIC VIEW OF THE CRYPTOCOCCUS SPECIES COMPLEXES

-AACR ANNUAL MEETING

APRIL 1-5, WASHINGTON, D.C.

-WORLD FEDERATION OF NEURO-ONCOLOGY SOCIETIES (WFNOS)

MAY 4-7, ZURICH, SWITZERLAND

H. DHUV, S. BOLLAM, H. KANG, S. PENG, V. GOKHALE, L. HURLEY, M. BERENS.

MTTERT PROMOTER AS A TARGET FOR TREATMENT OF GLIOBLASTOMA. OS01.3

D. FINLAY, H. DHUV, C. HAUSER, J. KIEFER, S. KIM, T. LONG, S. PENG, G.

SPEYER, M. BERENS, K. VUORI. NEW TARGETS FOR GLIOBLASTOMA REVEALED BY

CHEMICAL BIOLOGY FINGERPRINTING. P01.11

R. ALISON, M. SABIR, C. SEREDUK, S. TUNCALI, M. PINEDA, N. MILLARD, H. D.

DHUV, S. PENG, M. E. BERENS, J. C. LOFTUS, J. A. WINKLES, N. L. TRAN.

EGFRVIII INDUCED GBM INVASION AND SURVIVAL IS DEPENDENT UPON STAT5

ACTIVATION AND FN14 EXPRESSION. P08.02

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

-2017 GPU TECHNOLOGY CONFERENCE

MAY 7-11, SAN JOSE, CA

GIL SPEYER

S7254 - GPU-ENABLED DIFFERENTIAL DEPENDENCY NETWORK ANALYSIS OF LARGE DATASETS

-2017 ASCO

JUNE 2-6, CHICAGO, IL

TERESA MERCADE MACARULLA, JENS T. SIVEKE, ANDREA WANG-GILLAM, CHUNG-PIN LI, GYORGY BODOKY, ANDREW PETER DEAN, SHAN YANSHEN, GAYLE S. JAMESON, KYUNG-HUN LEE, JEAN-FRÉDÉRIC BLANC, CHANG-FANG CHIU, GILBERTO SCHWARTSMANN, FADI S. BRAITEH, DAVID CUNNINGHAM, LI-TZONG CHEN, DANIEL D. VON HOFF, KHALID KEVIN MAMLOUK, PARUL BHARGAVA, FLORIS A. DE JONG, RICHARD HUBNER. SUBGROUP ANALYSIS BY PRIOR LINES OF METASTATIC THERAPY (MTX) IN NAPOLI-1: A GLOBAL, RANDOMIZED PHASE 3 STUDY OF LIPOSOMAL IRINOTECAN (NAL-IRI) ± 5-FLUOROURACIL AND LEUCOVORIN (5-FU/LV), VS. 5-FU/LV IN PATIENTS (PTS) WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) WHO HAVE PROGRESSED FOLLOWING GEMCITABINE-BASED THERAPY. ABSTRACT NO: 4127

ANDREA WANG-GILLAM, LI-TZONG CHEN, CHUNG-PIN LI, GYORGY BODOKY, ANDREW DEAN, KYUNG-HUN LEE, DAVID CUNNINGHAM, RICHARD HUBNER, FADI S. BRAITEH, J. MARC PIPAS, BRUCE BELANGER, FLORIS A. DE JONG, PURVI D. MODY, DANIEL D. VON HOFF, JENS T. SIVEKE. THE PROGNOSTIC VALUE OF BASELINE NEUTROPHIL-TO-LYMPHOCYTE RATIO (NLR) AND PLATELET-TO-LYMPHOCYTE RATIO (PLR) FOR PREDICTING CLINICAL OUTCOME IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) TREATED WITH LIPOSOMAL

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

IRINOTECAN (NAL-IRI; MM-398) + 5-FLUOROURACIL AND LEUCOVORIN
(5-FU/LV) VS 5-FU/LV. ABSTRACT NO: E15795

DAVID GOLDSTEIN, DANIEL D. VON HOFF, E. GABRIELA CHIOREAN, MICHELE RENI,
JOSEP TABERNERO, RAMESH K. RAMANATHAN, ABDALLA ALY, MARC BOTTEMAN, JULIA
WILKERSEN, SANDRA MARGUNATO-DEBAY, BRIAN LU, CRYSTAL URSULA LOUIS,
MARKUS FREDERIC RENSCHLER, DESMOND MICHAEL THOMAS MCGOVERN, CHEE KHOON
LEE. NOMOGRAM FOR PREDICTING OVERALL SURVIVAL (OS) IN PATIENTS (PTS)
TREATED WITH NAB-PACLITAXEL (NAB-P) PLUS GEMCITABINE (GEM) OR GEM ALONE
FOR METASTATIC PANCREATIC CANCER (MPC). ABSTRACT NO: 4109

CHARLES PETERFY, XIN YE, HEATHER GELHORN, REBECCA M SPECK
PETER J. COUNTRYMAN, VICKI LEIGH KEEDY, ZEV A. WAINBERG, ARUN S. SINGH,
BARTOSZ CHMIELEWSKI, DANIEL D. VON HOFF, HANI M. BABIKER, VIVEK KHEMKA,
GREGORY MICHAEL COTE, GEOFFREY SHAPIRO, ANDREW J. WAGNER, JOHN H. HEALEY,
HENRY HSU, PAUL S. LIN, SANDRA TONG, WILLIAM D. TAP. TUMOR VOLUME SCORE
(TVS), MODIFIED RECIST, AND TISSUE DAMAGE SCORE (TDS) AS NOVEL METHODS
FOR ASSESSING RESPONSE IN TENOSYNOVIAL GIANT CELL TUMORS (TGCT) TREATED
WITH PEXIDARTINIB: RELATIONSHIP WITH PATIENT-REPORTED OUTCOMES (PROS).
ABSTRACT NO: 11048

-7TH INTERNATIONAL COCCIDIOIDOMYCOSIS SYMPOSIUM

AUGUST 10-13, STANFORD, CALIFORNIA

D. ENGELTHALER, GENETIC EPIDEMIOLOGY: TRACKING COCCI AROUND THE WESTERN
HEMISPHERE.

-NIA WORKSHOP

AUGUST 28, BETHESDA, MARYLAND

N. SCHORK, DISCOVERING AND VALIDATING DRUG TARGETS FOR ANTI-AGING USING
GENOMICS.

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

FULL-TIME POSITIONS FILLED (NEW AND REPLACEMENTS)

FROM JANUARY 1 THROUGH SEPTEMBER 30, 16 NEW FULL-TIME EQUIVALENT POSITIONS WERE CREATED WITH SALARIES AND BENEFITS TOTALING \$652,894.

SALARIES FOR TEMPORARY POSITIONS (THOSE POSITIONS CREATED FOR A FINITE PERIOD OF TIME) TOTALED \$136,453, WHICH INCLUDED TEMPORARY TGEN STAFF AND TEMPORARY SERVICE FEES. STUDENT SALARIES WERE JUST OVER \$286,600, BRINGING THE OVERALL 2017 TOTAL TO \$1,075,947.

IN TERMS OF EDUCATION LEVEL, EIGHTY-NINE PERCENT OF FULL-TIME TGEN STAFF HOLD A COLLEGE DEGREE AND FORTY-NINE PERCENT HOLD AN ADVANCED DEGREE.

2017 FULL-TIME POSITIONS FILLED (NEW AND REPLACEMENTS) INCLUDED:

- ACCOUNTS PAYABLE ADMINISTRATOR
- ADMINISTRATIVE ASSISTANT
- ADMINISTRATIVE ASSISTANT, EXECUTIVE
- ADMINISTRATIVE ASSISTANT, SR
- BIOINFORMATICIAN, ASSOCIATE
- BIOSPECIMEN DATA COORDINATOR
- CLINICAL RESEARCH COORDINATOR
- COMPUTATIONAL SCIENTIST
- DEPUTY DIRECTOR, CLINICAL SCIENCES
- DIRECTOR, DEVELOPMENT
- EDUCATION AND OUTREACH SPECIALIST

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

- INTELLECTUAL PROPERTY AND CONTRACTS DATABASE ASSISTANT
- MANAGER, RESEARCH OPERATIONS
- PATENT ATTORNEY
- PAYROLL ADMINISTRATOR
- POST-DOC FELLOW
- PROFESSOR
- PROFESSOR, ASSISTANT
- PROFESSOR, RESEARCH ASSISTANT
- PROFESSOR, RESEARCH ASSOCIATE
- RESEARCH ASSOCIATE
- RESEARCH ASSOCIATE II
- RESEARCH COMPLIANCE SPECIALIST
- RESEARCH TECHNICIAN

SELECT HIGHLIGHTS: EDUCATION AND OUTREACH

BIOSCIENCE LEADERSHIP ACADEMY

IN FEBRUARY, TGEN RECEIVED A THREE-YEAR GRANT OF \$346,000 FROM HELIOS EDUCATION FOUNDATION TO FUND A NEW TGEN PROGRAM FOR HIGH SCHOOL STUDENTS: TGEN BIOSCIENCE LEADERSHIP ACADEMY. THE ACADEMY IS A TWO-WEEK BIOSCIENCE PROGRAM, SERVING 20 ARIZONA HIGH SCHOOL STUDENTS EVERY SUMMER STARTING IN 2018. THE INTENSIVE EDUCATION AND LEADERSHIP PROGRAM FOCUSES ON ELEVATING STUDENTS' UNDERSTANDING OF THE BIOSCIENCES AND PRECISION MEDICINE. THE PROGRAM ALSO INCLUDES A LEADERSHIP COMPONENT FOCUSED ON STEM PROFESSIONAL SKILLS SUCH AS SCIENCE COMMUNICATION, PUBLIC SPEAKING, INTERDISCIPLINARY

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

AND COLLABORATIVE WORKPLACE SKILLS, AND NETWORKING. EACH GRADUATE OF THE PROGRAM WILL RECEIVE A \$1,000 SCHOLARSHIP.

HELIOS SCHOLARS AT TGEN

HELIOS SCHOLARS AT TGEN 2017 APPLICATIONS CLOSED ON FEBRUARY 10 AND ON JUNE 5, 45 ARIZONA STUDENTS BEGAN THEIR EIGHT-WEEK HELIOS SCHOLAR INTERNSHIPS, CONDUCTING RESEARCH PROJECTS IN TGEN LABS ON TOPICS, INCLUDING: NEUROLOGICAL DISEASE, CANCER, INFECTIOUS DISEASE, SEQUENCING, BIOINFORMATICS, AND RESEARCH ADMINISTRATION.

2017 HELIOS SCHOLAR STATISTICS:

-2017 SCHOLARS COMPRISED THE ELEVENTH CLASS, INCLUDING THE PILOT YEAR IN 2007

-10 HIGH SCHOOL STUDENTS, 33 UNDERGRADUATES AND 1 GRADUATE STUDENT, 1 MEDICAL SCHOOL STUDENT (45 INTERNS TOTAL.) ALONG WITH THE 45 HELIOS SCHOLARS, TWO HIGH SCHOOL STUDENTS STARTED 10-WEEK IVY SCHOLAR INTERNSHIPS.

-HIGH SCHOOLS INCLUDE: MCCLINTOCK HIGH SCHOOL, SCOTTSDALE PREPARATORY ACADEMY, HAMILTON HIGH SCHOOL, GARY K. HERBERGER YOUNG SCHOLARS ACADEMY, BASIS PEORIA, BASIS CHANDLER, FLAGSTAFF HIGH SCHOOL, AND ARIZONA SCHOOL FOR THE ARTS.

-29 UNDERGRADUATE/GRADUATE STUDENTS ATTENDING SCHOOL IN ARIZONA: 21 AT ASU, 2 AT U OF A, 3 AT NAU, 1 AT COCHISE COLLEGE, 1 AT MESA COMMUNITY COLLEGE, AND 1 AT MIDWESTERN UNIVERSITY

-SIX OUT-OF-STATE UNIVERSITIES: BAYLOR UNIVERSITY, BROWN UNIVERSITY,

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

CALIFORNIA POLYTECHNIC STATE UNIVERSITY, SCRIPPS COLLEGE, TULANE
UNIVERSITY, WILLAMETTE UNIVERSITY

-STUDENTS FROM EMERGING RACES/ETHNICITIES IN THE BIOLOGICAL SCIENCES
REPRESENT 22 PERCENT OF OUR COHORT.

ARIZONA SCIENCE AND ENGINEERING FAIR

TEN TGEN SCIENTISTS VOLUNTEERED ON APRIL 12 TO JUDGE AT THE 2017 ARIZONA
SCIENCE AND ENGINEERING FAIR (AZSEF). JULIE EUBER, MANAGER OF EDUCATION
AND OUTREACH AT TGEN, WAS THE AZSEF JUDGING CHAIR, SUPERVISING MORE THAN
300 JUDGES FROM ACROSS ARIZONA AND GUARANTEEING THAT EACH STUDENT WOULD
BE INTERVIEWED BY AT LEAST THREE JUDGES. FOR THE FOURTH YEAR, TGEN
AWARDED THE TGEN EXCELLENCE IN BIOMEDICAL RESEARCH AWARD TO TWO
OUTSTANDING HIGH SCHOOL PROJECTS THAT FOCUSED ON RESEARCH AND TECHNOLOGY
TO UNRAVEL THE COMPLEXITIES OF HUMAN DISEASES. NICOLE SHERWOOD AND DIVYA
VATSA WON THIS YEAR'S AWARD.

SELECT HIGHLIGHTS: COMMUNICATIONS

TGEN CONTINUALLY PURSUES EARNED MEDIA ABOUT THE INSTITUTE'S RESEARCH
ACTIVITIES. TGEN MEDIA RELEASES RESULTED IN NUMEROUS MEDIA MENTIONS
LOCALLY, NATIONALLY AND INTERNATIONALLY. MEDIA OUTLETS COVERING TGEN
INCLUDE:

THE ARIZONA REPUBLIC, PHOENIX BUSINESS JOURNAL, AZ BUSINESS MAGAZINE,
CHANNEL 3, CHANNEL 10, CHANNEL 12, CHANNEL 15, KJZZ RADIO, KTAR RADIO,
BBC NEWS (LONDON), THE STATE PRESS (ASU), WGRZ, WVEC, ALZHEIMER'S NEWS

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

TODAY, ARIZONA BIOINDUSTRY ASSOCIATION, GENOMEWEB DAILY NEWS, NEWS-MEDICAL.NET, FURNITURE TODAY, HOME FURNISHINGS BUSINESS, FAIRFAX COUNTY TIMES, THE ASCO POST, BUSINESS WIRE, FOX 26 HOUSTON, SCIENCE NEWSLINE, NEWSWISE, TECHCONNECT, NEW ORLEANS CITYBUSINESS, SCIENMAG, GENETIC ENGINEERING & BIOTECHNOLOGY NEWS.

2017 HIGHLIGHTS INCLUDE:

(A) TGEN PRESIDENT DR. JEFFREY TRENT AND CITY OF HOPE PRESIDENT ROBERT STONE WERE FEATURED IN AN 8-MINUTE SEGMENT ON CHANNEL 8'S ARIZONA HORIZON PROGRAM, DISCUSSING TGEN'S 15TH ANNIVERSARY AND TGEN'S NEW ALLIANCE WITH CITY OF HOPE.

(B) DR. JEFFREY TRENT PENNED AN EDITORIAL THAT APPEARED IN APRIL AS THE LEAD-CENTERPIECE FEATURE OF THE ARIZONA REPUBLIC'S SUNDAY VIEWPOINTS SECTION, DESCRIBING THE NEED FOR CONTINUED RESEARCH FUNDING FOR PRECISION MEDICINE. THE ON-LINE VERSION OF THE STORY CONTAINED MULTIPLE LINKS TO TGEN PRESS RELEASES, DETAILING THE VARIOUS RESEARCH PROJECTS MENTIONED BY DR. TRENT.

(C) TGEN RESEARCHERS WERE FEATURED IN MULTIPLE "ASK A DOC" FEATURES IN THE ARIZONA REPUBLIC, INCLUDING STORIES ABOUT TGEN'S RESEARCH INTO MELANOMA (DR. WINNIE LIANG), VALLEY FEVER (DR. DAVID ENGELHALER), CACHEXIA AND PANCREATIC CANCER (DR. HAIYONG HAN), AND BRAIN CANCER (DR. MICHAEL BERENS).

(D) IN MAY, YOUNG PATIENT CAMPBELL FAULKNER, TGEN C4RCD MEDICAL DIRECTOR DR. VINODH NARAYANAN AND C4RCD CLINICAL CO-DIRECTOR KERI RAMSEY WERE INTERVIEWED BY THE IHEARTRADIO NETWORK FOR BROADCAST ON ITS SEVEN

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

PHOENIX-AREA RADIO STATIONS ABOUT WHAT TGEN IS DOING FOR CHILDREN WITH RARE DISORDERS.

(E) IN AUGUST, ABC 15 REPORTED ON TGEN'S COLLABORATION WITH THE ARIZONA HUMANE SOCIETY TO STUDY DOGS WITH VALLEY FEVER.

(H) THAT SAME MONTH, 12 NEWS INTERVIEWED DR. PAUL KEIM ABOUT OUR PENDING FDA APPROVAL FOR A FAST AND ACCURATE TEST FOR VALLEY FEVER.

(F) IN JULY, ABC 15 REPORTED ON TGEN'S 11TH CLASS OF HELIOS SCHOLARS AT TGEN SUMMER INTERNSHIP PROGRAM.

(G) IN FEBRUARY, NPR AFFILIATE KJZZ RADIO FEATURED A STORY ABOUT DR. ISABELLE SCHRAUWEN'S C4RCD STUDY OF A 6-YEAR-OLD BOY WITH A RARE DISORDER CALLED FGS4.

(H) KJZZ FEATURED TGEN IN A STORY ABOUT HOW WE USE ZEBRA FISH TO STUDY PANCREATIC CANCER AND OTHER DISEASES.

(I) ALSO IN FEBRUARY, DR. BRIDGET BARKER WAS FEATURED IN THE BAKERSFIELD CALIFORNIAN, WHICH SOUGHT OUT HER EXPERTISE FOR A STORY ABOUT VALLEY FEVER.

FORM 990, PART V, LINES 1A AND 2A

TGEN FOUNDATION MAKES PAYMENTS TO INDEPENDENT CONTRACTORS AND TIMELY FILES FROM 1096 AS REQUIRED. HOWEVER, FORM 1096 WAS NOT FILED DURING THE FISCAL YEAR BECAUSE NO CALENDAR YEAR ENDED WITHIN THE SHORT PERIOD, 01/01/2017 - 09/30/2017.

FORM 990, PART V, LINE 2A; PART VII, SECTION A; AND PART IX

TGEN FOUNDATION DOES NOT HAVE EMPLOYEES, BUT SHARES THE COST OF

Name of the organization	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number	33-1092191
--------------------------	---	--------------------------------	------------

PERSONNEL, SERVICES, FACILITIES AND EXPENSES WITH TGEN, A RELATED TAX-EXEMPT ORGANIZATION.

FORM 990, PART VI, LINE 1A

TO THE EXTENT ALLOWED BY LAW, THE EXECUTIVE COMMITTEE MAY ACT ON TGEN FOUNDATION'S BEHALF IN ANY MATTER WHEN THE BOARD OF DIRECTORS IS NOT IN SESSION, REPORTING TO THE BOARD OF DIRECTORS FOR ITS INFORMATION AT THE NEXT SUBSEQUENT REGULAR OR SPECIAL MEETING OF THE BOARD. THE EXECUTIVE COMMITTEE CONSISTS OF THE DESIGNATED DIRECTORS, THE CHAIRPERSON OF THE BOARD AND UP TO THREE OTHER FOUNDATION DIRECTORS AS SHALL BE DESIGNATED BY THE BOARD OF DIRECTORS.

FORM 990, PART VI, LINE 6

THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION IS THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN).

FORM 990, PART VI, LINE 7A

TGEN, AS THE SOLE CORPORATE MEMBER OF TGEN FOUNDATION, HAS THE RIGHT TO ELECT THE BOARD OF DIRECTORS OF TGEN FOUNDATION.

FORM 990, PART VI, LINE 7B

CERTAIN ACTIONS MAY NOT BE UNDERTAKEN WITHOUT THE PRIOR WRITTEN APPROVAL OF THE SOLE CORPORATE MEMBER, TGEN, AS SPECIFIED IN THE GOVERNING DOCUMENTS OF THE FOUNDATION, INCLUDING: ELECT DIRECTORS; MERGE OR SELL ALL OR SUBSTANTIALLY ALL ASSETS; AMEND KEY GOVERNING DOCUMENTS; COMMENCE INSOVENCY, BANKRUPTCY, REORGANIZATION OR SIMILAR RELIEF OR ACTION; ENTER MATERIAL CONTRACTS OR

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

INCUR MATERIAL DEBT; AND TAKE SUCH OTHER ACTIONS RESERVED FOR THE MEMBER.

FORM 990, PART VI, LINE 11B

THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE TGEN FINANCE DEPARTMENT. THE FORM 990 IS THEN REVIEWED BY THE FINANCE DEPARTMENT, OTHER MEMBERS OF MANAGEMENT AND THE AUDIT AND COMPLIANCE COMMITTEE OF THE CITY OF HOPE. THE FORM 990 IS POSTED ON THE BOARD WEBSITE FOR BOARD REVIEW PRIOR TO FILING WITH THE IRS.

FORM 990, PART VI, LINE 12C

TGEN FOUNDATION DISTRIBUTES A CONFLICT OF INTEREST QUESTIONNAIRE ANNUALLY TO ALL DIRECTOR LEVEL POSITIONS AND ABOVE, IN ADDITION TO ANY OFFICERS AND KEY EMPLOYEES DESIGNATED BY THE TGEN CHIEF OPERATING OFFICER. THE QUESTIONNAIRES ARE REVIEWED BY THE TGEN CHIEF FINANCIAL OFFICER AND TGEN'S OFFICE OF RESEARCH COMPLIANCE. THOSE EMPLOYEES WITH CONFLICTS ARE SENT FOR FURTHER REVIEW TO THE TGEN CHIEF OPERATING OFFICER TO ENSURE AN APPROPRIATE PLAN IS SET FORTH. UPDATES TO THE LIST ARE HANDLED ON AN AS-NEEDED BASIS, BASED ON CONTRACT REVIEWS AND EMPLOYEE INFORMATION.

FORM 990, PART VI, LINES 15A AND 15B

THE FOUNDATION DOES NOT HAVE ANY DIRECT EMPLOYEES. COMPENSATION IS DETERMINED BY THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) USING THE FOLLOWING PROCESS:

THE EXECUTIVE COMPENSATION AND GOVERNANCE COMMITTEE OF THE MEMBER SHALL

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE FOUNDATION	Employer identification number 33-1092191
---	--

BE THE EXECUTIVE COMPENSATION COMMITTEE OF TGEN. NOTWITHSTANDING THE FOREGOING, TGEN'S GOVERNANCE AND EXECUTIVE COMPENSATION COMMITTEE WILL ACT IN AN "ADVISE AND CONSENT" CAPACITY REVIEWING THE RECOMMENDATIONS OF THE PRESIDENT AND SCIENTIFIC DIRECTOR REGARDING THE COMPENSATION OF DISQUALIFIED PERSONS CONSISTENT WITH THE MEMBER'S COMPENSATION PHILOSOPHY AND WITHIN THE COMPENSATION RANGES APPROVED AT LEAST ANNUALLY BY THE MEMBER, AND FORWARDING FINAL RECOMMENDATIONS TO THE FULL TGEN BOARD FOR APPROVAL.

DISQUALIFIED PERSONS (EXCEPT FOR THE PRESIDENT AND SCIENTIFIC DIRECTOR) WILL NOT BE PRESENT FOR, OR PARTICIPATE IN, COMMITTEE DELIBERATIONS CONCERNING THEIR COMPENSATION (OTHER THAN TO ANSWER QUESTIONS). THE PRESIDENT AND SCIENTIFIC DIRECTOR WILL PARTICIPATE IN THE DELIBERATIONS CONCERNING THE COMPENSATION OF DIRECT REPORTS.

DURING THE DECISION MAKING PROCESS, THE COMMITTEE WILL ADHERE TO THE EXECUTIVE COMPENSATION PHILOSOPHY OF THE MEMBER. THE COMMITTEE IS AUTHORIZED (AND PROVIDED WITH SUFFICIENT FUNDING) TO ANNUALLY ENGAGE OUTSIDE INDEPENDENT COMPENSATION AND LEGAL ADVISORS, WHEN DEEMED NECESSARY AND ADVISABLE.

THE COMMITTEE WILL COMPLY WITH THE "REBUTTABLE PRESUMPTION OF REASONABLENESS" UNDER SECTION 4958 OF THE INTERNAL REVENUE CODE WHENEVER POSSIBLE. THE COMMITTEE WILL REVIEW AND UNDERSTAND THE INTERNAL REVENUE CODE PROVISIONS DEALING WITH "EXCESS BENEFIT TRANSACTIONS CONCERNING

Name of the organization THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
FOUNDATION

Employer identification number
33-1092191

DISQUALIFIED PERSONS' COMPENSATION."

WHEN DEVELOPING A COMPENSATION PHILOSOPHY, TGEN KEPT IN MIND THE
FOLLOWING FACTORS:

- THE TGEN MISSION AND STRATEGY
- THE TGEN CULTURE
- TRENDS IN COMPENSATION IN THE EXTERNAL ENVIRONMENT
- TRENDS IN RECRUITMENT OF NEW EMPLOYEES
- TRENDS IN ORGANIZATIONAL EMPLOYEE TURNOVER
- TGEN'S LIFE CYCLE STAGE

THE COMPENSATION REVIEW PROCESS WAS LAST COMPLETED IN 2017.

FORM 990, PART VI, LINE 19

THE FOUNDATION'S ARTICLES OF INCORPORATION ARE AVAILABLE TO THE PUBLIC
THROUGH THE ARIZONA CORPORATION COMMISSION. THE FOUNDATION'S AUDITED
FINANCIAL STATEMENTS AND ITS CONFLICT OF INTEREST POLICIES ARE AVAILABLE BY
WRITTEN REQUEST MADE TO THE CFO AND CONFLICT OF INTEREST MANAGER,
RESPECTIVELY. THE FOUNDATION'S BYLAWS ARE NOT MADE AVAILABLE TO THE
PUBLIC.

**SCHEDULE R
(Form 990)**

Department of the Treasury
Internal Revenue Service

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
FOUNDATION

Related Organizations and Unrelated Partnerships

▶ Complete if the organization answered "Yes" on Form 990, Part IV, line 33, 34, 35b, 36, or 37.

▶ Attach to Form 990.

▶ Go to www.irs.gov/Form990 for instructions and the latest information.

OMB No. 1545-0047

2017

Open to Public
Inspection

Employer identification number
33-1092191

Part I Identification of Disregarded Entities. Complete if the organization answered "Yes" on Form 990, Part IV, line 33

(1)	(a) Name, address, and EIN (if applicable) of disregarded entity	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Total income	(e) End-of-year assets	(f) Direct controlling entity
(1)						
(2)						
(3)						
(4)						
(5)						
(6)						

Part II Identification of Related Tax-Exempt Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related tax-exempt organizations during the tax year

(1)	(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Exempt Code section	(e) Public charity status (if section 501(c)(3))	(f) Direct controlling entity	(g) Section 512(b)(13) controlled entity?	
							Yes	No
(1)	THE TRANSLATIONAL GENOMICS RESEARCH INST 445 N 5TH STREET, SUITE 600 PHOENIX, AZ 85004	RESEARCH	AZ	501(C)(3)	7	N/A		X
(2)	CITY OF HOPE 1500 EAST DUARTE ROAD DUARTE, CA 91010	FUNDRAISING	CA	501(C)(3)	7	N/A		X
(3)	CITY OF HOPE NATIONAL MEDICAL CENTER 1500 EAST DUARTE ROAD DUARTE, CA 91010	HOSPITAL	CA	501(C)(3)	3	CITY OF HOPE	X	
(4)	BECKMAN RESEARCH INSTITUTE 1450 EAST DUARTE ROAD DUARTE, CA 91010	RESEARCH	CA	501(C)(3)	4	CITY OF HOPE	X	
(5)	CITY OF HOPE MEDICAL FOUNDATION 1500 EAST DUARTE ROAD DUARTE, CA 91010	HEALTHCARE	CA	501(C)(3)	3	CITY OF HOPE	X	
(6)								
(7)								

For Paperwork Reduction Act Notice, see the Instructions for Form 990.

Schedule R (Form 990) 2017

JSA

7E1307 1 000
8938EH 1546

60103263

PAGE 62

Part III Identification of Related Organizations Taxable as a Partnership. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a partnership during the tax year

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Predominant income (related, unrelated, excluded from tax under sections 512 - 514)	(f) Share of total income	(g) Share of end-of-year assets	(h) Disproportionate allocations?		(i) Code V - UBI amount in box 20 of Schedule K-1 (Form 1065)	(j) General or managing partner?		(k) Percentage ownership
							Yes	No		Yes	No	
(1)												
(2)												
(3)												
(4)												
(5)												
(6)												
(7)												

Part IV Identification of Related Organizations Taxable as a Corporation or Trust. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, because it had one or more related organizations treated as a corporation or trust during the tax year.

(a) Name, address, and EIN of related organization	(b) Primary activity	(c) Legal domicile (state or foreign country)	(d) Direct controlling entity	(e) Type of entity (C corp, S corp, or trust)	(f) Share of total income	(g) Share of end-of-year assets	(h) Percentage ownership	(i) Section 512(b)(13) controlled entity?	
								Yes	No
(1)									
(2)									
(3)									
(4)									
(5)									
(6)									
(7)									

Part V Transactions With Related Organizations. Complete if the organization answered "Yes" on Form 990, Part IV, line 34, 35b, or 36.

Note: Complete line 1 if any entity is listed in Parts II, III, or IV of this schedule

	Yes	No
1 During the tax year, did the organization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?		
a Receipt of (i) interest, (ii) annuities, (iii) royalties, or (iv) rent from a controlled entity		X
b Gift, grant, or capital contribution to related organization(s)	X	
c Gift, grant, or capital contribution from related organization(s)	X	
d Loans or loan guarantees to or for related organization(s)	X	
e Loans or loan guarantees by related organization(s)	X	
f Dividends from related organization(s)	X	
g Sale of assets to related organization(s)	X	
h Purchase of assets from related organization(s)	X	
i Exchange of assets with related organization(s)	X	
j Lease of facilities, equipment, or other assets to related organization(s)	X	
k Lease of facilities, equipment, or other assets from related organization(s)		X
l Performance of services or membership or fundraising solicitations for related organization(s)		X
m Performance of services or membership or fundraising solicitations by related organization(s)		X
n Sharing of facilities, equipment, mailing lists, or other assets with related organization(s)		X
o Sharing of paid employees with related organization(s)		X
p Reimbursement paid to related organization(s) for expenses		X
q Reimbursement paid by related organization(s) for expenses		X
r Other transfer of cash or property to related organization(s)		X
s Other transfer of cash or property from related organization(s)		X

	(a) Name of related organization	(b) Transaction type (a-s)	(c) Amount involved	(d) Method of determining amount involved
(1)				
(2)				
(3)				
(4)				
(5)				
(6)				

Part VI **Unrelated Organizations Taxable as a Partnership.** Complete if the organization answered "Yes" on Form 990, Part IV, line 37

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization. See instructions regarding exclusion for certain investment partnerships.

(1) Name, address, and EIN of entity	(2) Primary activity	(3) Legal domicile (state or foreign country)	(4) Predominant income (related, unrelated, excluded from tax under sections 512-514)	(5) Are all partners section 501(c)(3) organizations?		(6) Share of total income	(7) Share of end-of-year assets	(8) Disproportionate allocations?		(9) Code V - UBI amount in box 20 of Schedule K-1 (Form 1065)	(10) General or managing partner?		(11) Percentage ownership
				Yes	No			Yes	No		Yes	No	
(1)													
(2)													
(3)													
(4)													
(5)													
(6)													
(7)													
(8)													
(9)													
(10)													
(11)													
(12)													
(13)													
(14)													
(15)													
(16)													

Part VII Supplemental Information

Provide additional information for responses to questions on Schedule R See instructions